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ABSTRACT

STRUCTURAL DETERMINANTS FOR INHIBITOR RECOGNITION
BY THE DOPAMINE TRANSPORTER

By
Yi Liu
May 2011

Dissertation supervised by Professor Christopher K. Surratt
The dissertation will give an introduction, background and our research progress
in the areas of dopamine transporter (DAT).

A 3-D DAT computer model was

generated in our laboratory based on the X-ray crystal structure of the bacterial leucine
transporter LeuT, a distant homolog of DAT. The ability of this LeuTAa-based 3-D DAT
computer model to identify specific DAT residues involved in inhibitor recognition was
assessed

through

site-directed

mutagenesis

and

subsequent

pharmacologic

characterization in the present study. Feedback from these experiments confirmed some
of the suggestion from the DAT model, which is encouraging that the comparative DAT
model is valid to some extent and could be further used for ligand docking and virtual
screening.

iv

Non-tropane

based

photoaffinity

labeling

compounds

were

also

pharmacologically characterized to identify potential probes that could unveil direct
covalent contacts between the DAT protein and the non-tropane drug. One
methylphenidate analog was identified among a series of compounds, and was further
radiolabeled and successfully incorporated into the DAT protein. Subsequent feedback
from the crosslinking/proteolysis study could also refine the 3-D DAT model.
The refined DAT model was used for in silico screening of candidate ligands.
Ten “hit” compounds were pharmacologically tested. Three of them displayed moderate
binding affinities to DAT, supporting the use of combined approaches including
molecular modeling, mutagenesis and crosslinking/proteolysis for rational drug design of
novel pharmacotherapeutic ligands to treat psychostimulant addiction and other
monoamine-related CNS disorders.

v

DEDICATION

Dedicated To My Family For Their Love And Support

vi

ACKNOWLEDGEMENT

I would like to thank all of those who have contributed to this work.
In particular I am most grateful to Professor Dr. Christopher K. Surratt, my
supervisor, for his help and support that made this dissertation possible. I am indebted to
him not just for his scientific contribution but also for his motivating words, financial
support and his friendship.
I would like to thank the members of my dissertation committee: Drs. Jeffry
Madura, Paula A.Witt-Enderby, David A. Johnson, Wilson S. Meng and Christopher K.
Surratt for their scientific and emotional support.
I wish to express my sincere appreciation to Deborah Willson, Nancy Hosni,
Jackie Farrer and Mary Caruso in the office of pharmacy school for their help and
assistance. My thanks goes to all my colleagues in the Graduate School of
Pharmaceutical Sciences for their help and advice which made my stay at Duquesne
University a most pleasant experience. I would like to thank the Graduate School of
Pharmaceutical Sciences for the financial support provided to me.
Finally, I would like to pay tribute to the constant support of my family and my
friends, without their love over the many years none of this would have been possible and
whose sacrifice I can never repay. A very special thanks goes to my husband, Lei, for
helping me complete my dissertation in time.

vii

TABLE OF CONTENTS
Page
Abstract .............................................................................................................................. iv
Dedication .......................................................................................................................... vi
Acknowledgement ............................................................................................................ vii
List of Tables .......................................................................................................................x
List of Figures ................................................................................................................... xii
List of Abbreviations .........................................................................................................xv
Introduction ..........................................................................................................................1
A. Overview .............................................................................................................1
B. Statement of the Problem ....................................................................................6
C. Literature Survey ...............................................................................................20
Materials and Methods .......................................................................................................38
A. Materials and Equipment ..................................................................................38
B. Methodology and Procedures ............................................................................48
Results and Discussion ......................................................................................................59
A. Pharmacological characterization of DAT mutants ..........................................59
1. Results ............................................................................................................59
2. Discussion ......................................................................................................68
B. Pharmacological characterization of analogs of classic non-tropane DAT
inhibitors ............................................................................................................................79
1. Results ............................................................................................................79
2. Discussion ......................................................................................................86
viii

C. Pharmacological characterization of novel DAT ligands identified through in
silico screening using the DAT model ...............................................................................91
1. Results ............................................................................................................91
2. Discussion ....................................................................................................105
Summary ..........................................................................................................................108
Bibliography ....................................................................................................................110
Appendix 1 .......................................................................................................................125
Appendix 2 .......................................................................................................................126
Appendix 3 .......................................................................................................................131
Appendix 4 .......................................................................................................................132
Appendix 5 .......................................................................................................................133
Appendix 6 .......................................................................................................................134

ix

LIST OF TABLES
Page
Table 1. Affinity of WIN 35,428 at N2A neuroblastoma cells or COS 7 cells transiently
expressing DAT constructs ................................................................................................63
Table 2. Binding affinity and DUIP of cocaine at N2A neuroblastoma cells or COS 7
cells transiently expressing DAT constructs ......................................................................65
Table 3. Binding affinity and DUIP of benztropine at N2A neuroblastoma cells or COS 7
cells transiently expressing DAT constructs ......................................................................67
Table 4. DAT binding affinities and dopamine uptake inhibition potencies (DUIPs) of
non-tropane based DAT ligands at hDAT N2A neuroblastoma cells................................81
Table 5. DAT binding affinities and dopamine uptake inhibition potencies of
methylphenidate-based DAT ligands at hDAT N2A neuroblastoma cells ........................85
Table 6. DAT binding affinities and dopamine uptake inhibition potencies of MI hits at
hDAT N2A neuroblastoma cells ........................................................................................95
Table 7. Binding and substrate uptake inhibition of MI-17 and its analog (DJLDU 3-79)
at hDAT-N2A and HEK-hSERT cells ...............................................................................99
Table 8. Affinity of MI-4 at N2A neuroblastoma cells transiently expressing DAT
constructs .........................................................................................................................104
Table 9. Affinity of Modafinil at N2A neuroblastoma cells transiently expressing DAT
constructs .........................................................................................................................128
Table 10. Affinity of [125I]-iodomelatonin at CHO cells stably expressing MT1
constructs .........................................................................................................................138

x

Table 11. Affinity of melatonin and luzindole at CHO cells stably expressing MT1
constructs .........................................................................................................................140

xi

LIST OF FIGURES
Page
Figure 1. Schematic representation of dopaminergic neurotransmission ...........................5
Figure 2. Big picture of the study .......................................................................................9
Figure 3. DAT side chains implicated in recognition of cocaine and benztropine ...........12
Figure 4. Schematic representation of crosslinking analysis ............................................16
Figure 5. Chemical structures of tropane-based and non-tropane-based DAT inhibitors 17
Figure 6. Schematic illustration of virtual screening approach ........................................19
Figure 7. Schematic illustration of DAT topology ...........................................................23
Figure 8. Schematic illustration of transport mechanism and inhibition in LeuT ............26
Figure 9. The structures of DAT substrates .......................................................................27
Figure 10. The structures of tropane-based DAT inhibitors ..............................................28
Figure 11. The structures of non-tropane-based DAT inhibitors .......................................30
Figure 12. Determination of [3H]-WIN35,428 specific binding and [3H]-dopamine
uptake ability by COS-7 or N2A cells expressing WT or mutant DAT proteins ..............61
Figure 13. Chemical structures of non-tropane based compounds and their analogs .......80
Figure 14. Chemical structures of methylphenidate (1) and its analogs (2-18) ................84
Figure 15. Photoaffinity labeling of DAT with [125I]-(+)-13 ............................................90
Figure 16. Chemical structures of virtual screening “hit” compounds employed in [3H]WIN35,428 displacement and [3H]-dopamine uptake inhibition assays ..........................92
Figure 17. Initial DAT binding affinity and dopamine uptake inhibition screening for
MI-11 to MI-20 at N2A neuroblastoma cells stably expressing WT hDAT .....................93

xii

Figure 18. MI-15, MI-17 and MI-20 DAT binding affinity and dopamine uptake
inhibition potency in N2A cells .........................................................................................94
Figure 19. Initial SERT binding affinity and serotonin uptake inhibition screening for
MI-11 to MI-20 at HEK cells stably expressing WT hSERT ............................................98
Figure 20. MI-4 decreases the DUIP of cocaine ............................................................101
Figure 21. MI-4 docking in the DAT model ..................................................................103
Figure 22. Clomipramine inhibition of [3H]-WIN35,428 binding at N2A cells transiently
expressing WT or D384A DAT .......................................................................................125
Figure 23. Affinity and DUIP of modafinil at hDAT/N2A neuroblastoma cells ..........126
Figure 24. Modafinil decreases the DUIP of cocaine ....................................................127
Figure 25. Inhibition of [3H]-WIN35,428 specific binding by cocaine, modafinil and
MI-4 at N2A cells expressing WT or mutant DAT proteins ...........................................130
Figure 26. Initial DAT binding affinity and dopamine uptake inhibition screening for
VS “non-hit” compound at N2A neuroblastoma cells stably expressing WT hDAT ......131
Figure 27. Affinity of WIN 35,428 at N2A neuroblastoma cells transiently expressing
HA tagged DAT ...............................................................................................................132
Figure 28. Affinity of MI-4 at N2A neuroblastoma cells transiently expressing T472
DAT .................................................................................................................................133
Figure 29. Determination of [125I]-iodomelatonin specific binding by COS 7 cells
expressing WT or N6.52 mutant MT1 receptor proteins .................................................136
Figure 30. Specific [125I]-iodomelatonin binding at CHO cells stably expressing WT or
N6.52A MT1 receptor proteins ........................................................................................137

xiii

Figure 31. Specific [125I]-iodomelatonin binding at CHO cells stably expressing WT or
N6.52A MT1 receptor proteins ........................................................................................139

xiv

LIST OF ABBREVIATIONS

DA - Dopamine
DAT - Dopamine transporter
NSS - Neurotransmitter:sodium symporter
DUIP - Dopamine uptake inhibition potency
NET - Norepinephrine transporter
SERT - Serotonin transporter

xv

I. INTRODUCTION

A. Overview
Dopamine (DA), a major neurotransmitter in the mammalian central nervous
system, mediates a wide array of physiological functions including regulation of
locomotor activity, cognitive processes, neuroendocrine secretion, and the control of
motivated behaviors. It is biosynthesized from the amino acid tyrosine and stored in
synaptic vesicles. In response to a presynaptic action potential, DA is released into the
synapse by Ca2+-mediated exocytosis, where it binds to the dopamine receptors on the
neighboring neuron and activates dopaminergic signal transduction pathways (Fig. 1).
Dysfunctions in the DA system are believed to contribute to the development of several
neurological and psychiatric conditions such as Parkinson’s disease, depression,
schizophrenia, attention deficit hyperactivity disorder (ADHD) and drug addiction
(Schultz 2002; Arias-Carrion, Stamelou et al. 2010).

The neurotransmission of DA is terminated primarily by reuptake of DA into the
presynaptic cell via the dopamine transporter (DAT). Thus, DAT plays a critical role in
regulating the signal amplitude and duration of dopaminergic neurotransmission by
mediating the reuptake of the transmitter from the extracellular space back into nerve
terminals. DAT belongs to the neurotransmitter: sodium symporter (NSS) family, also
1

referred to as the SLC6 (solute carrier 6) family (Saier 1999), that includes transporters
for norepinephrine, serotonin, glycine and GABA (Amara and Kuhar 1993). These
transporters utilize the transmembrane Na+ gradient as a driving force for transport of
substrate across the plasma membrane. They are also characterized by co-transport of Cl-.
The reuptake process involves a conformational change in the transporter protein
(Rudnick and Clark 1993). The mechanism of the translocation process includes at least
three iconic states: outward-facing (open to outside), occluded, and inward-facing (open
to inside) (Yamashita, Singh et al. 2005). The outward-facing transporter recognizes and
binds Na+, Cl- and substrate.

The binding of substrate and ions triggers the

conformational change to an inward-facing conformation, allowing the release of the
substrate and ions to the cytoplasm.
DAT is expressed almost exclusively in the areas of the brain with established
dopaminergic circuitry: nigrostriatal, mesolimbic and mesocortical pathways (Ciliax,
Heilman et al. 1995; Ma, Ciliax et al. 1999). The mesolimbic and mesocortical pathways
play key roles in reward assessment.

Dopaminergic projections from the ventral

tegmental area (VTA) to the limbic areas (nucleus accumbens, ventral striatum and
amygdala) comprise the mesolimbic pathway, while projections from the VTA to the
medial, prefrontal, cingulated and entorhinal cortex comprise the mesocortical pathway
(Marsden 2006). The nigrostriatal pathway (substantia nigra to the caudate putamen) is
associated with locomotor activity.
The DAT is a target of several clinically used drugs, including the
psychostimulants

methylphenidate,

D-amphetamine,
2

and

modafinil

and

the

antidepressant bupropion. In addition, the reinforcing and euphoric effects of the
powerfully addictive psychostimulants cocaine and d-methamphetamine (“crystal meth,”
a vastly more potent analog of amphetamine, often administered in large doses by
vaporization) are primarily mediated by interaction with the DAT (Mortensen and Amara
2003; Torres 2006). Such drugs bind to DAT and inhibit the reuptake of dopamine
(Kuhar, Ritz et al. 1991). In addition to inhibiting uptake of extracellular dopamine,
amphetamines also stimulate efflux of intracellular dopamine (Kahlig, Binda et al. 2005).
The

resultant

accumulation

of

dopamine

in

the

synaptic

cleft

potentiates

neurotransmission of dopamine in those areas of the brain associated with reward and
reinforcement.

Consequently, the motor and reward pathways of the midbrain are

activated, triggering the increased locomotor activity and euphoria associated with
psychostimulant drug use.
Studies using mice lacking DAT demonstrated the importance of the transporter
in psychostimulant action.

DAT knockout mice display an attenuated response to

cocaine and amphetamines and a reduced preference for cocaine under selfadministration paradigms (Giros, Jaber et al. 1996). These mice, however, still selfadminister cocaine, although more sessions were needed to meet self-administration
criteria (Rocha, Fumagalli et al. 1998). The finding indicated that developmentally
compensatory non-dopaminergic mechanisms can mediate cocaine-taking behavior in
DAT-lacking animals. In particular, cocaine’s interaction with the serotonin transporter
(SERT) has been hypothesized to contribute to cocaine reward and reinforcement
naturally or in compensation for the absence of DAT (Rocha, Fumagalli et al. 1998;
Mateo, Budygin et al. 2004). Nevertheless, convincing preclinical evidence implicating
3

specific activity at the DAT in cocaine dependence comes from the observation that the
reinforcing effect of cocaine is lost in transgenic mice expressing a triple point-mutated
DAT with preserved substrate translocation but little appreciable affinity for cocaine
(Chen, Tilley et al. 2006). It is conceivable that elevated basal dopaminergic tone in
these mice causes adaptive changes, altering the response to cocaine; however,
knockdown mutant mice with a ~ 90% reduction in DAT expression but with
functionally unmodified DATs and elevated basal dopamine still exhibit robust,
wildtype-like preference for cocaine. Interaction with the DAT is thus necessary for the
reinforcing effects of cocaine in animals that carry the DAT (Tilley, Cagniard et al. 2007).

4

Figure 2. Schematic representation of dopaminergic neurotransmission.
Dopamine, synthesized in the presynaptic neuron, is stored in the synaptic
vesicles. Following the arrival of an action potential, dopamine is released into the
synaptic cleft by Ca2+-mediated exocytosis. Dopamine binds to the dopamine receptors
on the postsynaptic neurons and transmits neuronal signals. Neurotransmission is
terminated primarily by reuptake of dopamine into the presynaptic neuron via the DAT.
Cocaine blocks the dopamine reuptake and increases synaptic dopamine concentrations.
Amphetamine promotes dopamine efflux as well as competes with dopamine for reuptake.
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B. Statement of the problem
Cocaine abuse and addiction continues to be a significant public health problem in
the world. In the United States, the number of regular cocaine users has not declined
significantly since 1992.

The National Survey on Drug Use and Health (NSDUH)

estimates that in 2009 there were 1.6 million current cocaine users aged 12 or older,
comprising 0.7 percent of the population, similar to the number and rate in 2008. Drug
abuse generally inflicts severe medical, social and judicial costs upon the society. The
central problem with cocaine addiction is that the risk for relapse is high even after
treatment and extended periods of abstinence. During periods of abstinence, the memory
of the cocaine experience associated with drug use can trigger tremendous craving and
relapse to drug use (Anker and Carroll 2010; Saunders and Robinson 2010). Cocaine
addiction contributes to several medical, psychiatric and psychosocial problems, even the
spread of human immunodeficiency virus/acquired immune deficiency syndrome
(HIV/AIDS) and viral hepatitis (as a consequence of sharing contaminated needles).
Cocaine use is associated with alertness, increased energy and motor activity,
enhancement of sensation, and euphoria (Preti 2007). The abuse liabilities of cocaine
result from its euphorigenic and reinforcing properties.

The reinforcing effects of

cocaine and its analogs generally correspond with the ability of the drug to inhibit the
DAT, and thus to potentiate dopamine neurotransmission. Blockade of this protein
increases synaptic levels of the neurotransmitter dopamine in the nucleus accumbens and
other brain regions critical to euphoria and addiction (Ritz, Lamb et al. 1987). Cocaine
also increases synaptic concentrations of serotonin and norepinephrine by blockade of the
cognate transporters, resulting in stimulant and mood-altering effects (Amara and Kuhar
6

1993; Torres 2006). Despite extensive research, medications that combat the actions of
cocaine and other psychostimulants at the level of the DAT protein are currently
unavailable and desperately needed. To understand the function and regulation of DAT
could provide rational design for developing useful compounds in combating
psychostimulant abuse and addiction. However, the limited information on the structure
and function of DAT has hindered research progress.
Obtaining high-resolution DAT structure-function information is therefore key to
understanding psychostimulant mechanisms of action, and in subsequent developing
useful therapeutics against psychostimulant abuse and addiction. The 2005 publication of
a crystal structure for a NSS/SLC6 homolog, the bacterial leucine transporter LeuT
(Yamashita, Singh et al. 2005), provided the first reasonable template for threedimensional comparative modeling of NSS proteins. A LeuTAa-directed DAT model was
generated using the capabilities of the Molecular Operating Environment (MOE) program
(Indarte, Madura et al. 2008). The LeuT crystal suggests that the substrate leucine and
sodium ions are tethered midway through the lipid bilayer in a pocket created primarily
by the middle, unwound portions of TM 1 and TM 6. The unwound regions of TM 1 and
TM 6 are also postulated to be involved in the interconversion of outward- and inwardfacing transporter conformations (Yamashita, Singh et al. 2005). The conformational
changes with respect to substrate access are governed by the opening and closing of
external and internal “gates”. The external gate is of special interest, as it may be
relevant to inhibitor action (Yamashita, Singh et al. 2005). Recent published LeuTtricyclic antidepressant (TCA) co-crystal structures indicate that the position of TCA
drugs is several Angstroms (Å) above the substrate pocket, sitting on the closed external
7

gate (Singh, Yamashita et al. 2007; Zhou, Zhen et al. 2007). Docking of cocaine to the
LeuTAa-based DAT model yielded a binding site coinciding with that of TCA drugs in the
published LeuT cocrystal structures.
The hypothesis of this study is that a LeuTAa-based 3-D DAT molecular model
can be used to reveal the ligand binding sites, and as a tool for in silico screening of
candidate ligands that may serve as lead compounds in development of novel medications
to combat addiction, depression, Parkinson’s disease, and other DA system related
dysfunctions. The ability of this LeuTAa-based 3-D DAT computer model to identify
specific DAT residues involved in inhibitor recognition was assessed through sitedirected mutagenesis and subsequent pharmacologic characterization in the present study.
In addition, non-tropane based photoaffinity labeling compounds were also
pharmacologically characterized to identify potential probes that could unveil direct
covalent contacts between the DAT protein and the non-tropane drug. Feedback from
site-directed mutant pharmacology and crosslinking/proteolysis studies will refine the 3D DAT model as a drug screening tool for new potential ligands, aiding the development
of non-addictive drugs for treating addiction (Fig. 2). Therefore, the specific aim 1 of this
study is to determine the role of amino acid residues predicted by the DAT model to be
involved in inhibitor recognition. The specific aim 2 is to pharmacologically characterize
analogs of non-tropane inhibitors for further development of potential probes to detect the
specific non-tropane drug-DAT contact. The specific aim 3 is to pharmacologically
characterize the novel DAT ligands identified through in silico screening using the DAT
model.
8

Figure 2. Big picture of the study.
The 3-D DAT model was created by Dr. Martin Indarte.

9

The overall goal of this study is to identify specific DAT residues involved in
inhibitor recognition, using DAT molecular modeling, site-directed mutagenesis,
pharmacologic characterization, and DAT ligand covalent crosslinking analysis. The
study involved three experimental approaches: 1) DAT residues identified by the DAT
molecular model as key to inhibitor recognition were mutated and pharmacologically
characterized to verify the inhibitor binding site predicted by the DAT model.

2)

Analogs of the non-tropane inhibitors pyrovalerone, bupropion and methylphenidate were
pharmacologically characterized toward developing potential probes to detect specific
non-tropane drug-DAT protein contacts. 3) The novel DAT ligands identified through in
silico screening were pharmacologically characterized to verify the ability of the DAT
model to discover novel ligands that may carry therapeutic promise.
These three approaches were detailed as follows:
1) Site-directed mutagenesis – the specific hypothesis to be tested is that DAT model
docking algorithms can predict inhibitor binding sites that can be verified via
mutagenesis and pharmacology.
From the docking simulations between the DAT model and inhibitor ligands,
several DAT amino acid residues were selected as site-directed mutagenesis targets. In
this case, cocaine and benztropine were docked with the DAT model because they are
suggested to prefer outward- and inward-facing DAT conformations, respectively
(Loland, Desai et al. 2008). Amino acids within 7 Å of the drug were considered for
mutagenesis. A residue as far as 7 Å away would not directly contact the ligand, but
could contribute pocket infrastructure that confers binding selectivity. Ten amino acids
10

suggested from the docking results were selected as the site-directed mutagenesis targets
(Fig. 3).

11

Figure 3. DAT side chains implicated in recognition of cocaine and benztropine.
Docking of cocaine (Panel A, 3-D representation; Panel B, 2-D representation) or
benztropine (Panel C, 3-D representation; Panel D, 2-D representation) using the 3-D
DAT model (created by Dr. Martin Indarte) is shown. Side chains within 7 Angstroms of
the ligand are pictured.
12

The side chain of R85 (TM1) appears selectively important for benztropine
recognition due to hydrophobic interactions between the hydrocarbon portion of the side
chain and aromatic rings of the inhibitor, H-bonding with the ether moiety of the drug.
D475 (TM 10) could potentially interact with the protonated N-8 tropane atom of cocaine.
The model also indicated that R85 seems to form a salt bridge with D475 (TM 10) that
stabilizes the inhibitor binding site. Moreover, the DAT R85 – D475 salt bridge appears
to line the floor of the cocaine/TCA binding pocket. The presence of a salt bridge was
tested by creation of double mutants in which the side chains at the bridging positions are
switched (Sahin-Toth, Dunten et al. 1992; Merickel, Kaback et al. 1997).

In this case,

the switch mutant would be R85D / D475R. Restoration of wildtype-like transporter
function in the switch mutant when each single mutation disrupts function can be taken as
evidence of the presence of the salt bridge. Confirmation of the DAT model-predicted
intratransmembranous salt bridge would verify the TM1-TM10 juxtaposition and provide
an important advance in understanding DAT structure and function. Thus, single mutants
R85D and D475R and the switch mutant R85D /D475R were created.
K92 (TM 1) appears to hydrophobically interact with the inhibitors through the
straight chain hydrocarbon. Additionally, a salt bridge with the TM 6 D312 carboxylate
may provide DAT infrastructure. To verify the presence of the ion pair, single mutants
K92D and D312K and the switch mutant K92D/D312K were created.
Y88 (TM 1) and F542 (TM 11) appear to form π-π stacking with aromatic rings of
both cocaine and benztropine aromatic groups in the DAT model. Y88 can also H-bond
with the C-2 ester of cocaine. These two residues were selected to be mutated to alanine.
13

Alanine substitution could eliminate aromaticity but preserve the α-helical nature of the
transmembrane domain.
H476 (TM 10) is unique to the DAT. This residue appears likely to form Hbonding or hydrophobic interactions with cocaine, but not benztropine.

Alanine

replacement removes any significant partial positive charge, H-bonding, side chain length
and any π electron contributions while preserving the α-helical nature of the
transmembrane domain.
G425 (TM 8) is conserved among the monoamine transporters (DAT, SERT and
NET). The analogous position in LeuT is occupied by I359, which is important for the
binding site of LeuT (Yamashita, Singh et al. 2005).

Isoleucine substitution should

lengthen the side chain and increase the steric hindrance; moreover, it may change the
binding site to mimic that of LeuT.
D384 (TM 8) and I468 (TM 10) are shown only in the “gate closed” binding
conformation for cocaine and benztropine. D384 was mutated to alanine or asparagine,
while cysteine and alanine replaced I468. For D384, alanine substitution could remove
any significant charge and H-bonding potential, while asparagine replacement eliminates
the negative charge of aspartic acid but retains the side chain length and H-bonding
potential. For I468, alanine substitution would shorten the side chain length and decrease
the size of the side chain, while cysteine replacement could shorten the side chain length
and add H-bonding potential. Moreover, alanine is shown in SERT as analogous to
isoleucine in DAT and NET.

Cysteine mutation could be further used in

methanethiosulfonate (MTS) alkylation assays that test accessibility to the residue.
14

T472 (TM 10) directly contacts cocaine in the “gate closed” poses, and also in the
“gate open” pose for benztropine in the DAT model. Alanine replacement shortens the
side chain and eliminates the potential for H-bonding but preserves the α-helical nature of
the transmembrane domain. Lysine substitution will lengthen the side chain and preserve
the H-bonding potential. Moreover, lysine is found in the analogous position of the SERT;
therefore, mutants T472A and T472K were generated.
The engineered plasmids encoding the DAT mutations were transiently
introduced into N2A neuroblastoma cells via the calcium phosphate-DNA precipitation
technique (Graham and van der Eb 1973) and tested via radioligand binding and uptake
assays.
2) Non-tropane inhibitor analog characterization – the specific hypothesis to be tested is
that a specific non-tropane drug-DAT protein contact can be detected, toward
mapping the drug binding site.
Non-tropane-based photoaffinity ligands for the DAT are relatively unexplored, in
contrast to tropane-based compound such as cocaine and benztropine. Therefore, novel
non-tropane analogs for pyrovalerone, bupropion and methylphenidate were synthesized
by Dr. Lapinsky’s lab and pharmacologically characterized in the present study. Those
displaying high DAT affinity were radiolabeled and crosslinked to the DAT protein via
photolysis. Upon photolysis of the [125I]-labeled drug, a reactive nitrene group on the
drug will form a covalent bond with the nearest appropriate DAT residue.

DAT

proteolysis and western blotting with one of many epitope position-specific DAT
antibodies will identify the DAT region corresponding to the radiolabeled fragment (Fig.
15

4). The DAT model will indicate the most likely residue(s) for the point of crosslink, and
these targets will be addressed via site-directed mutagenesis.

Figure 4. Schematic representation of crosslinking analysis.
Photoaffinity labeling probe will covalently bind to the target protein through
reactive group (e.g. nitrene) crosslinking. The complex will then be fragmented. The
radiolabeled fragment will be purified and identified through western blot assay.
16

Using stably-transfected N2A cells bearing WT hDAT, all non-tropane analogs
from the Lapinsky lab were assessed for binding affinity (measured by [3H]-WIN 35,428
displacement) and [3H]-dopamine uptake inhibition potency (DUIP). Compounds with
low nanomolar DAT affinities and potencies were forwarded to the Lever lab for
radioiodination, and then to the Vaughan lab for crosslinking, proteolysis and analysis.
O
O

O
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N

N

O
Cocaine

Benztropine

NH

O

N
Cl
O
Pyrovalerone

CH3

NH O

O
Bupropion

Methylphenidate

Figure 5. Chemical structures of tropane-based and non-tropane-based DAT
inhibitors.
The tropane moiety is highlighted with the dashed circle in the structures of
cocaine and benztropine.
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3) Characterization of virtual screening “hit” compounds – the specific hypothesis to be
tested is that the DAT model can be used for virtual screening to discover novel
ligands that may carry therapeutic promise.
Inhibitor binding pocket, defined by the refined model, was unveiled to be located
in the vestibule area. This vestibule pocket was then used for virtual screening of a
structure library of compounds. Top ranked virtual screening (VS) “hit” compounds
(predicted to be high affinity at the DAT) from the in silico screen were purchased and
tested at the bench via DAT binding/uptake assays using the N2A DAT cell line (Fig. 6).

18

Figure 6. Schematic illustration of virtual screening approach.
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C. Literature Survey
1.

Structure of the Dopamine Transporter
The human DAT, which is located in chromosome 5p15.3 (Giros, Jaber et al.

1996), encodes 620 amino acids in its primary sequence.

Up to date, no X-ray

crystallographic or high-resolution structural information is available for the topological
assignments of DAT, or any other member of the family of mammalian monoamine
transporters (MATs).

Hydropathy analysis (Kilty, Lorang et al. 1991; Shimada,

Kitayama et al. 1991) of the primary sequences of MATs predicts a topology with 12
transmembrane-spanning

segments

connected

by

alternating

extracellular

and

intracellular loops with the amino and carboxyl termini located in the cytosol (Fig. 7).
This theoretical arrangement has been at least partially confirmed by experimental
evidence.

A study using cysteine/lysine-modifying reagents and biotinylated probe

scanning has demonstrated the proposed topology on predicting extracellular domains of
the serotonin transporter (Chen and Justice 1998). The intracellular location of the Nterminus and the extracellular location of the loop between TM 3 and TM 4 have been
confirmed by the immunoperoxidase and immunogold electron microscopy, using
monoclonal antibodies specific for the N-terminus and the second extracellular loop
(Nirenberg, Vaughan et al. 1996; Hersch, Yi et al. 1997). By use of proteolysis and
epitope-specific immunoprecipitation of photolabeled DAT, it demonstrates the presence
of at least one transmembrane helix or other membrane-anchoring structures in two
different regions of the protein predicted to contain transmembrane domains and again
identifies the extracellular orientation of the region between TM 3 and TM 4 (Vaughan
20

and Kuhar 1996).

Experiments with membrane permeable and impermeable Cys-

selective chemical modification reagents confirm the extracellular location of C90 and
C306, and intracellular locations of C135 and C342 in human DAT (hDAT) (Ferrer and
Javitch 1998). In addition, three residues on the extracellular face of the hDAT (H193,
H375, and E396), have been characterized to form three coordinates in the Zn2+-binding
site. The common participation of these amino acids in binding the Zn2+ ion suggests a
close proximity between extracellular loop 2, TM 7, and TM 8 in the tertiary structure of
the hDAT (Norregaard, Frederiksen et al. 1998; Loland, Norregaard et al. 1999).
DAT is a glycoprotein with an apparent molecular mass of ~80 kDa as
determined by gel electrophoresis. N-deglycosylation of DAT by glycosidase reduces the
molecular mass to ~50 kDa (Vaughan and Kuhar 1996; Patel 1997). Several putative Nglycosylation sites are found in the second extracellular loop located between TM 3 and
TM 4. Mutagenesis studies have demonstrated that the glycosylation is critical for the
activity and stability of the DAT at the surface (Torres, Carneiro et al. 2003; Li, Chen et
al. 2004). The stability and trafficking of the human norepinephrine transporter (hNET)
to the membrane has been shown largely dependent on glycosylation of the consensus
sites (Melikian, Ramamoorthy et al. 1996; Nguyen and Amara 1996).
Two cysteines (C180 and C189) in the second extracellular loop, conserved in
MATs, are predicted to form a disulfide bond in DAT. Substitution of these cysteine
residues dramatically reduced the cell surface expression of rat DAT (rDAT) or SERT
proteins (Wang, Moriwaki et al. 1995; Chen, Liu-Chen et al. 1997).

Random

mutagenesis at either or both cysteines impaired the function of mutated drosophila
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DATs.

Furthermore, a mutated drosophila DAT with all cysteines removed except the

two cysteines in extracellular loop 2 (ECL2) demonstrated the presence of disulfide
bridge. The breaking of the disulfide bond by DTT treatment did not affect transport
activity (Chen, Wei et al. 2007). These results suggest that the disulfide bridge between
these cysteines in ECL2 is essential for DAT biosynthesis and its delivery to the cell
surface, but not necessary for its uptake function.
The primary sequence of DAT contains several predicted protein kinase sites in
the putative intracellular domains (Kilty, Lorang et al. 1991; Shimada, Kitayama et al.
1991). Mutagenesis studies have revealed phosphorylation sites for Protein Kinase C
(PKC), PI-3 kinase and ERK1/2 (Chang, Lee et al. 2001; Lin, Zhang et al. 2003). A
cluster of six serines, located at the distal end of the DAT N-terminal via enzymatic
cleavage, phopho-peptide mapping, amino acid analysis and truncation studies (Foster,
Pananusorn et al. 2002), are phosphorylated following PKC activation or phosphatase
inhibition (Foster, Pananusorn et al. 2002; Granas, Ferrer et al. 2003; Cervinski, Foster et
al. 2005).

Several serines and threonines are also found located at the N-terminal more

proximal to the membrane, containing consensus motifs for PKC, Protein Kinase A (PKA)
and proline-directed kinases (Gorentla, Moritz et al. 2009). Serine and threonine residues
at DAT C-terminal have been suggested as potential phosphorylation sites for PKC, PKA
and proline-directed kinases (Chang, Lee et al. 2001; Gorentla, Moritz et al. 2009). PKC
mediated DAT phosphorylation has been suggested to cause the sequestration of the
transporter protein (Zhu, Kavanaugh et al. 1997; Melikian and Buckley 1999) and
downregulation of transporter activity (Huff, Vaughan et al. 1997; Vaughan, Huff et al.
1997). While a recent mutagenesis study found that the elimination of PKC mediated N22

tail DAT phosphorylation fails to prevent the internalization of the transporter, implying
that N-terminal phosphorylation is not important for DAT internalization (Chang, Lee et
al. 2001; Granas, Ferrer et al. 2003).

Threonines on the proximal of N-terminal are

phosphorylated by proline-directed kinases (e.g. ERK1/2, p38MAPK and JUN).
Moreover, T53 is indicated as the phosphorylation site of ERK1/2 (Gorentla, Moritz et al.
2009). The functional implication of T53 and other amino acids associated with DAT
phosphorylation has not yet determined.

Figure 7. Schematic illustration of DAT topology.
The dopamine transporter has 12 transmembrane domains and a large second
extracellular loop with several putative N-glycosylation sites. Both N- and C-termini are
located on the intracellular side of the membrane with several predicted protein kinase
sites.
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2.

Mechanism of Substrate Transport
The reuptake of monoamine is driven by the ion concentration gradient that is

generated by the plasma membrane Na+/K+ ATPase. In the case of DAT, two Na+ ions
and one Cl- ion are transported with the substrate, while SERT and NET co-transport
their respective substrates with one Na+ ion and one Cl- ion. SERT additionally transports
K+ in antiport fashion (Rudnick and Clark 1993; Torres, Gainetdinov et al. 2003).
Na+/Cl- – dependent transporters, like many ion channels, have selective binding sites for
substrate and ions. However, these transporters, unlike most ion channels, are believed to
possess two “gates” that can alternately allow access to the binding sites from either side
of the membrane bilayer (Jardetzky 1966; Johnson, Eshleman et al. 1998; Pifl and Singer
1999). Binding of dopamine, Na+ and Cl- to DAT on the extracellular side induces a
conformational change in the transporter allowing the exposure of the binding site to the
intracellular side of the membrane. Dopamine and the ions are translocated into the cell
and the empty transporter returns to the outward facing conformation to initiate another
transport cycle (Reith 1997; Zhang and Rudnick 2006).
The crystal structure of LeuTAa (NSS/SLC6 homolog) unveils the amino acid
residues and TMs that compromise the extracellular and intracellular gates, as well as
conformational changes that the transporter might undergo during the translocation cycle.
Extracellular gate of LeuTAa, is formed primarily by Y108 (TM 3), F258 (TM 6), R30
(TM 1) and D404 (TM 10). In contrast to extracellular gate, intracellular gate is more
substantial, involving R5 (TM 1), W8 (TM 1), D369 (TM 10), T265 (TM 6), S267 (TM 6)
and T268 (TM 6). At least three conformational states are suggested to occur during the
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transport process: open-to-outside (outward facing), occluded (substrate and ion bound)
and open-to-inside (inward facing) (Yamashita, Singh et al. 2005).
Outward facing conformation allows substrate and ions binding. The binding of
substrate and ions trigger the conformation transitions to the occluded (substrate- and ionbound) state, and subsequent inward facing conformation allowing the release of
substrate and ions into the cytoplasm (Fig. 8, A, B and C). Although the substrate and
ion binding sites are accessible from both sides of the membrane, the access from the
extracellular side is suggested to be easier than access from the intracellular side, given
the fact that the ‘thickness’ of protein occluding the substrate/ion binding pockets from
the extracellular side of the membrane is much smaller than that shielding the binding site
from the cytoplasmic side. Moreover, compared to the intracellular gate, less substantial
extracellular gate or barrier might allow substrates and ions to bind and unbind more
quickly from the extracellular side in comparison with the cytoplasmic side. Thus, the
transporter may tend to preferentially stay in outward facing state, ready for substrates
and ions binding (Gouaux 2009).
With respect to inhibition of substrate translocation by inhibitors, distinct steps of
transport cycle are postulated to be involved (Fig 8, D and E). In the case of LeuTAa,
competitive inhibitor displaces the substrate and traps the transporter in an open-to-out
conformation, thereby preventing progression to the next transport step (occluded state).
Whereas non-competitive inhibitor binds to the secondary binding pocket and stabilizes
the transporter in the occluded state, thus preventing the translocation cycle (Singh,
Piscitelli et al. 2008).
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Figure 8. Schematic illustration of transport mechanism and inhibition in LeuT
(Singh, Piscitelli et al. 2008)
A mechanism to describe the activity of LeuT that involves binding of substrates
and ions to an open-to-the outside conformation (A), isomerization to an occluded state
(B), and subsequent isomerization to an open-to-the-inside conformation (C), and from
the open-to-in (C) back to the open-to-out state (A). Effect of the competitive inhibitor
Trp on transporter: stabilizing the open-to-out conformation (D). Effect of the
noncompetitive TCA inhibitors on transport-stabilizing the outward-facing occluded
conformation (E). The boxed conformations represent actual crystal structures, whereas
the unboxed conformations are hypothetical.
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3.

Substrate and Inhibitor Selectivity of the DAT

3.1 DAT Substrates
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Methamphetamine R = CH3

MDMA

Figure 9. The structures of DAT substrates.
Amphetamines
The most commonly studied DAT substrates are amphetamines, including
amphetamine and methamphetamine (Fig. 9). S-(+)-amphetamine releases dopamine
with an EC50 of 8.7 nM; the R-(−)-amphetamine is 3-fold weaker, at 27.7 nM (EC50)
(Blough, Page et al. 2005). Although weaker, a similar trend is seen for the optical
isomers of methamphetamine. S-(+)-methamphetamine releases dopamine with an EC50
of 24.5 nM, while the R-(−)-methamphetamine is 16-fold less active at 416 nM (EC50)
(Blough, Page et al. 2005).
MDMA
MDMA (Fig. 9), a 3,4-methylenelioxy analog of methamphetamine, is much
weaker than amphetamine as a dopamine releaser. MDMA releases dopamine with an
EC50 value of 278nM, compared to the more potent compound amphetamine (EC50 = 8.7
nM) (Rothman and Baumann 2006).
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3.2 DAT Inhibitors
3.2.1 Tropane-Based DAT inhibitors
H3C
N

H3C
N
CO2CH3

H3C
N
CO2CH3
R

O

O

O
Cocaine

WIN 35,065 R = H
WIN 35,428 R = F

Benztropine

Figure 10. The structures of tropane-based DAT inhibitors.
WIN Compounds
Due to the significant abuse and dependence liability of cocaine, analogs of
cocaine were synthesized in the early 1970s in the hope of finding a useful stimulant or
antidepressant. Some of the most potent behavioral stimulants that were discovered at
this time were later known as WIN 35,065 and WIN 35,428 (Fig. 10) (Clarke 1977).
These compounds were analogs of cocaine in which the benzoyl ester has been replaced
by a phenyl group linked directly to the tropane ring. WIN 35,065 and WIN 35,428 were
16- and 64-times as active as cocaine, respectively, in terms of their potency to increase
locomotor activity in mice, and WIN 35,428 was described as lasing for more than 5
hours (Clarke, Daum et al. 1973). [3H]WIN 35,428, a radiolabelled form of WIN 35,428
has been used in determination of DAT ligand binding affinity.
Benztropine
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Benztropine (Fig. 10) is a drug that has been clinically used for many years as an
adjunct therapy to reduce motor side effects associated with neuroleptic treatment with
antipsychotic medications. Benztropine is a molecule with the shared features of a
tropane ring from cocaine and a diphenyl ether of the phenylpiperazines. There are
several lines of evidence that suggest that the benztropine bind differently than cocaine to
the DAT and that those difference in interaction, at the molecular level, may be related
the actions of benztropine analogs that differ from those of cocaine (Newman and
Kulkarni 2002). Early studies employing site-directed mutagenesis of the DAT revealed
differences in binding modes between cocaine and benztropine (Reith, Berfield et al.
2001). In contrast to cocaine, benztropine had no effect on the reaction of Cys-90 with a
thiosulfonate reagent. In addition, the decrease in the reaction of Cys-135 with a
thiosulfonate reagent produced by cocaine and other DA-uptake inhibitors was not
obtained with benztropine (Reith, Berfield et al. 2001). Several other studies have
demonstrated differences in the actions of benztropine or its analogs with wild-type and
mutant DAT (Chen, Zhen et al. 2004). Studies using photoaffinity labeling techniques
have also provided evidence that structurally different dopamine uptake inhibitors
covalently attach to different TMs in the DAT (Vaughan, Agoston et al. 1999; Zou,
Kopajtic et al. 2001).
3.2.2 Non-Tropane-Based DAT inhibitors
GBR compounds
GBR compounds resulted from the replacement of the tropane ring in benztropine
by a piperazine ring. These compounds represent structurally important class of potent
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and selective dopamine reuptake inhibitors (Newman and Kulkarni 2002). GBR 12909
and GBR 12935 (Fig. 11) were among the first agents to characterized as high-affinity
and selective inhibitors of DAT. Further work identified these compounds as moderately
selective inhibitors of dopamine uptake over serotonin and norepinephrine uptake (Preti
2000). Early studies with GBR 12909 noted that it differed from cocaine in several key
ways (Rothman and Glowa 1995). GBR 12909 has a slower onset of action and longer
duration of action than that of cocaine (Rothman, Grieg et al. 1992). It possesses a much
higher affinity for, and slower dissociation rate from, the DAT than cocaine (Rothman,
Mele et al. 1991). It functionally antagonizes cocaine’s ability to elevate extracellular
levels of dopamine (Rothman, Mele et al. 1989; Rothman, Mele et al. 1991) and has a
nonstimulant-like profile in normal human volunteers following oral administration
(Sogaard, Michalow et al. 1990).

Figure 11. The structures of non-tropane-based DAT inhibitors.
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Mazindol
Mazindol (Fig. 11) is a sympathomimetic amine that is marketed as an
anorexigenic by several companies and is the major representative of a class of dopamine
uptake inhibitors. For a time, it was the tritiated ligand used to measure binding at the
DAT. The behavior effects of mazindole were compared with cocaine using squirrel
monkeys trained to respond under a fixed-interval schedule of stimulus-shock termination.
Mazindol displayed behavioral effects that were qualitatively similar to those of cocaine,
producing dose-related increases in response rates Mazindol was only slightly less potent
than cocaine in producing this effect (Spealman, Madras et al. 1989).
Bupropion
Bupropion (Fig. 11) is another dopamine-uptake inhibitor that is typically studied
as standard DAT inhibitor. It is currently marketed as antidepressant and smoking
cessation aid. Like cocaine, it is a locomotor stimulant. Despite the fully cocaine-like
profile of bupropion in animal models, it typically does not produce a cocaine-like
discriminative stimulus effect in human (Rush, Kollins et al. 1998), and it is not generally
abused.
Methylphenidate
Like mazindol and bupropion, methylphenidate (Fig. 11) is a dopamine-uptake
inhibitor that has been clinically use for the treatment of attention-deficit hyperactivity
disorder and narcolepsy for many years, and despite similarities to cocaine, has not been
widely abused. Methylphenidate has also been used as a standard dopamine-uptake
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inhibitor in studies determining the contribution of the uptake inhibitor to the behavioral
effects of cocaine and other ligands.
4.

Structure-Function Analysis of the DAT
Knowledge of DAT functional group topography is a prerequisite for

understanding the molecular basis of transporter function, the actions of psychostimulant
drugs, and mechanisms of dopaminergic neurodegeneration. Thus, extensive efforts have
been made to identify the amino acid residues and the domains that participate in
substrate binding and translocation, and inhibitor binding.

Prior to the publication of

LeuT crystal structure, approaches such as site-directed mutagenesis, chimeric
transporters and substituted cysteine accessibility method (SCAM) have been employed
in structure-function studies.
Substrate transport- and inhibitor-binding functions have been identified within
the DAT TM 1-3 and 4-8 regions by using DAT/NET chimeras (Buck and Amara 1994;
Giros, Wang et al. 1994; Buck and Amara 1995). Cross-species chimera using bovine
and human DAT implicated the involvement of TM 3, 6 and 8 in cocaine binding and DA
transport (Lee, Kang et al. 1998; Lee, Chang et al. 2002). By use of an irreversible
affinity labeling approach, binding sites for cocaine, benztropine and GBR classes of
uptake inhibitors have been investigated. N-terminal (TM 1and 2) and or/central (TMs 4
to 7) of DAT has been identified as binding regions (Vaughan and Kuhar 1996; Vaughan,
Agoston et al. 1999; Vaughan, Gaffaney et al. 2001; Vaughan, Sakrikar et al. 2007). The
attachment site of one of the cocaine analogs (RTI-82) has been further localized to TM 6
(Vaughan, Sakrikar et al. 2007).

Taken together, results of these two approaches
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correspond well with the contributions of TMs 1, 3, 6 and 8 to the substrate pocket in
LeuTAa, and also strongly suggest the three-dimensional proximity and contribution of
TMs 1, 3 and 6 for cocaine binding.
Site-directed mutagenesis is another approach employed in structure-function
studies.

To date, over 250 amino acid residues in rDAT and hDAT have been

investigated and reviewed (Surratt, Ukairo et al. 2005; Volz and Schenk 2005). Mutation
of many residues leads to modest reduction in cocaine binding or transport, consistent
with indirect effects on the active site structure. Several mutations that affect cocaine
affinity do so by inhibiting ion-binding or ion-transport conformational changes rather by
directly affecting ligand- or DA-binding sites (Chen, Rickey et al. 2004; Chen, Zhen et al.
2004; Loland, Granas et al. 2004). D79 was the first DAT residue shown to be critical
for transport (Kitayama, Shimada et al. 1992). This residue is conserved in NSSs, and its
mutation also strongly inhibits cocaine binding. Its importance for transport and inhibitor
binding has been supported by similar results from SERT (Barker, Moore et al. 1999) and
by the finding that the analogous residue is present in the LeuTAa Na+ binding site
(Yamashita, Singh et al. 2005). D79 is suggested to be present within the DAT active
site and compensates for the lack of a negative charge on DA by coordinating one of the
cotransported Na+ ions (Wang, Sonders et al. 2003; Yamashita, Singh et al. 2005). A
nearby TM 1 residue F76 is indicated to be involved in constructing the active site, given
the observation that mutation of this residue result in lowered cocaine affinity (Lin, Wang
et al. 1999). This residue corresponds to N21 in LeuTAa, which participates in substrate
binding (Yamashita, Singh et al. 2005), and Y95 in SERT, which is implicated in
substrate and ligand binding (Henry, Adkins et al. 2003; Henry, Field et al. 2006). These
33

data support the importance of this position in the NSS binding pocket. V152 in TM 3
also has good support for direct involvement in transport and cocaine binding, based on
chimeric switches, multiple substitution analysis, and homology to a SERT inhibitor
contact point at I172 (Henry, Adkins et al. 2003; Henry, Field et al. 2006) and a LeuTAa
leucine contact point at V104 (Lee, Chang et al. 2000). F319 and G323 of rDAT within
TM 6, analogous to LeuTAa active-site phenylalanine and serine residues, cause the loss
of essential all transport activity when mutated, consistent with roles in transport.
Simultaneous mutation of three TM2 residues, L104, F105, and A109, leads to
loss of cocaine binding with maintenance of DA transport (Wu and Gu 2003; Chen, Han
et al. 2005). However, LeuTAa structure and SCAM (substituted cysteine accessibility
method) analysis of DAT (Sen, Shi et al. 2005) support the interpretation that this TM is
found outside the active-site core and acts as a structural support for TM6, suggesting the
likelihood that the TM2 mutations affect cocaine binding indirectly by leading to
misalignment of TM6. These studies highlight the importance of the overall transporter
structure in maintenance of proper function, the apparent ease with which indirect effects
can be transmitted to active site, and the challenges in determining DAT structurefunction relationships from mutagenesis.
Several residues involved in conformational changes occurring during the
translocation cycle have also been identified. Mutations at W84, K264, D313, Y335,
D345 and D346 result in loss of transport activity and alterations in cocaine binding
(Chen, Rickey et al. 2004; Chen, Zhen et al. 2004; Loland, Granas et al. 2004). Analysis
of the ionic and Zn2+ dependence of these mutants suggest that the mutations suppress
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transport by stabilizing particular structures of the protein, indicating that the wild-type
residues participate in intermolecular interactions necessary for conformational
rearrangements during the transport cycle. In these studies it was also found that DATs
locked in outward-facing conformations displayed increased cocaine affinity, whereas
those locked in inward-facing conformations displayed decreased cocaine affinity (Chen,
Rickey et al. 2004; Chen, Zhen et al. 2004), consistent with the cocaine-binding pocket
being formed by an extracellular-facing form of the protein.
SCAM study, determining the sensitivity of endogenous and exogenous cysteine
residues to reactivity with sulfhydryl-modifying reagents, has also been used for studying
the DAT structure and function. By utilizing this approach, aqueously accessible regions
in interhelical loops, DA or ligand access pathways, and non-accessible regions adjacent
to membrane lipids or other protein structure could be identified. To date, data from
SCAM studies confirm the 12 TM topology of the DAT, which is consistent with other
research results.

Furthermore, SCAM has also been used to detect conformational

changes in the DAT. Some residues are reveled to be involved in DA transport and
cocaine binding, including C90, R219, C342, M371 and D436 (Ferrer and Javitch 1998;
Chen, Ferrer et al. 2000; Norregaard, Loland et al. 2003).
5.

LeuTAa and DAT
One of the major challenges to understanding how the DAT and related

neurotransmitter transporters function has been the limited knowledge of the protein
structure.

The sites of action for DA and ions, the nature of the conformational

rearrangements that drive transport and the mechanisms by which cocaine and other
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blockers bind to DAT and prevent transport are poorly understood. None of the NSS
proteins has been crystallized, and there is currently only limited experiment evidence
pertaining to their 3-D structures.

In 2005, a breakthrough in this area was the

determination of a high-resolution crystal structure of LeuTAa, a Na+-dependent bacterial
leucine transporter (Yamashita, Singh et al. 2005). Although only distantly related in
amino acid sequence, this transporter is functionally homologous to the NSSs, and it is
currently expected to provide an important template for interpretation and direction of
DAT structure-function studies.
In LeuTAa, TMs 1 to 5 and 6 to 10 form structural cassettes oriented to each other
by a pseudo 2-fold axis, with TMs 1, 3, 6 and 8 forming a central core that creates a
binding pocket for leucine and Na+. The leucine- and Na+- binding sites are found about
half way across the membrane and are in close proximity, consistent with a substrate
moving as a unit. In the crystallized structure, these binding sites are occluded from the
aqueous medium by the external and internal gates, suggesting that the transport
mechanism involves a minimum of three conformations: outward-facing, occlude and
inward-facing.

High-resolution crystallographic studies of LeuT in complex with

multiple tricyclic antidepressants (TCAs) showed that one TCA molecule bound at the
base of the extracellular vestibule, further occluding leucine and the two sodium ions
(Singh, Yamashita et al. 2007; Zhou, Zhen et al. 2007). The location of the TCA
molecule indicates an inhibitor binding site (secondary substrate site, S2) distinguished
from the primary leucine binding site (S1).
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A 3-D DAT model based on LeuTAa crystal structure also identified two similar
binding sites (Indarte, Madura et al. 2008; Shi, Quick et al. 2008; Quick, Winther et al.
2009). S2 site for the DAT is located several angstroms to the extracellular side of the S1
site, serving as a substrate staging area prior to passage through the external gate (Indarte,
Madura et al. 2008; Shi, Quick et al. 2008). Unlike TCA binding in LeuTAa, cocaine and
benztropine are believed to bind in the S1 site (Beuming, Kniazeff et al. 2008; Bisgaard,
Larsen et al. 2011).
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II. MATERIALS AND METHODS
A. Materials and Equipment
1. Facilities
Laboratories – Mellon Hall of Science, Room 408, 414, 456, 457 and 459
2. Cell lines
Murine neuroblastoma (N2A) cells stably expressing wildtype rat DAT
N2A cells
COS 7 (African green monkey kidney) cells
3. Chemicals and Drugs
Fetal bovine serum
Thermo Scientific, Logan, UT
Dulbecco’s Modified Eagle Medium (DMEM)
Thermo Scientific, Logan, UT
Opti-MEM I Reduced Serum Medium
Invitrogen, Carlsbad, CA
Dulbecco’s Phosphate Buffered Saline (DPBS) Ca/Mg-free
Cambrex Bioscience Walkersville Inc., MD
G-418 sulfate
Clontech Laboratories Inc., CA
L-Glutamine
Invitrogen, Carlsbad, CA
Penicillin-Streptomycin
Gibco-BRL, Grand Island, NY
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Compressed carbon dioxide
Air Products, Pittsburgh, PA
Ampicillin sodium salt
Acros, NJ
Trypsin-EDTA 10X
Gibco-BRL, Grand Island, NY
[3H]-Dopamine
Perkin Elmer, Foster City, CA
[3H]-WIN 35, 428
Perkin Elmer, Foster City, CA
Acetic acid, glacial
Fisher Scientific, Pittsburgh, PA
Agarose
Invitrogen Corporation, Carlsbad, CA
Bio-Rad protein assay dye reagent concentrate
Bio-Rad Laboratories Inc., Hercules, CA
Bovine serum albumin
Sigma Chemical Co., St. Louis, MO
Calcium chloride
Sigma-Aldrich Co., St. Louis, MO
D-(+)-Glucose
Sigma-Aldrich Co., St. Louis, MO
dNTP mix
Stratagene, La Jolla, CA
DH5α cells
Invitrogen, Carlsbad, CA
Dimethylsulfoxide (DMSO)
Sigma Chemical Co., St. Louis, MO
EcoR1
Invitrogen, Carlsbad, CA
EDTA
Sigma-Aldrich Co., St. Louis, MO
Ethanol 200 proof
Pharmaco Products Inc., Brookfield, CT
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Ethanol, HPLC grade
Acros, NJ
Ethidium bromide
Fisher Scientific, Pittsburgh, PA
Glycerol
Fisher Scientific, Pittsburgh, PA
Glycine
Sigma-Aldrich Co., St. Louis, MO
HEPES free acid
MP Biomedicals Inc., Solon, OH
HBSS/modified
Hyclone, Logan, UT
Isopropanol (DNase, RNase and protease free)
Fisher Scientific, Pittsburgh, PA
LB agar
Fisher Scientific, Pittsburgh, PA
LB broth
Fisher Scientific, Pittsburgh, PA
MAB369 Rat anti-Dopamine Transporter
Chemicon International, Temecula, CA
Methanol, HPLC grade
Fisher Scientific, Pittsburgh, PA
Paraformaldehyde
Sigma Chemicals Co., St. Louis, MO
TransIT-LT1 Transfection Reagent
Mirus Coporation, Madison, WI
Polymerase, Pfu Turbo
Stratagene, La Jolla, CA
Potassium chloride
Sigma-Aldrich Co., St. Louis, MO
Potassium phosphate, monobasic
Sigma Chemical Co., St. Louis, MO
Primers
Operon, Huntsville, AL
RNase A (DNase free)
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Fisher Scientific, Pittsburgh, PA
SOC media
Invitrogen, Carlsbad, CA
ScintiSafe scintillation fluid
Fisher Scientific, Pittsburgh, PA
Sodium Chloride
Sigma-Aldrich Co., St. Louis, MO
Sodium Hydroxide
Fisher Scientific, Pittsburgh, PA
Sodium Hydroxide 2N solution
Fisher Scientific, Pittsburgh, PA
Sodium Hydroxide 12N solution
Fisher Scientific, Pittsburgh, PA
Sodium lauryl sulfate
Sigma Chemical Co., St. Louis, MO
T4 DNA ligase
Invitrogen, Carlsbad, CA
Tris-EDTA buffer (DNase, RNase and protease free)
Acros, NJ
Tris free base
Fisher Scientific, Pittsburgh, PA
Tris-HCl salt
Sigma Chemical Co., St. Louis, MO
Triton X-100
Acros, NJ
PshAI
New England Biolabs, Ipswich, MA
BsiWI
New England Biolabs, Ipswich, MA
Clomipramine hydroxide
Tocris bioscience, Elllisville, MO
Benztropine methane-sulfonate
Sigma Chemical Co., St. Louis, MO
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4. Materials
Cell culture flasks, 75cm2
Corning Inc., Teterboro, NY
Cell culture grade water
Hyclone, Logan, UT
Cell culture plates (10, 25cm)
Fisher Scientific, Pittsburgh, PA
Centrifuge tube, 15ml
Corning Inc., Horseheads, NY
Centrifuge vials, 1.5ml
Corning Inc., Horseheads, NY
Culture tubes, disposable
Fisher Scientific, Pittsburgh, PA
Falcon tubes, 14ml
Fisher Scientific, Pittsburgh, PA
Falcon tubes, 50ml
Fisher Scientific, Pittsburgh, PA
Filter unit, sterile
Millipore, Billerica, MA
Eppendorf microcentrifuge tubes, 1.5 ml
Fisher Scientific, Pittsburgh, PA
Parafilm
Fisher Scientific, Pittsburgh, PA
Pasteur pipettes, disposable
Fisher Scientific, Pittsburgh, PA
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Pipette tips, disposable Redi-Tips TM (1, 10, 200, 1000 µl)
Fisher Scientific, Pittsburgh, PA
Polaroid film
Fisher Scientific, Pittsburgh, PA
Polypropylene tubes
Fisher Scientific, Pittsburgh, PA
Respirator
Fisher Scientific, Pittsburgh, PA
Scintillation vials
Fisher Scientific, Pittsburgh, PA
Serological pipettes, sterile disposable (5, 10, 25 ml)
Fisher Scientific, Pittsburgh, PA
Syringes, sterile (10 ml)
Fisher Scientific, Pittsburgh, PA
Thermowell PCR tubes
Corning, Horseheads, NY
Tissue culture plates, sterile (6 well, 24 well)
Fisher Scientific, Pittsburgh, PA
Sarstedt Inc., Newton, NC

Kits
Gel extraction kit
Qiagen Inc., Valencia, CA
PCR purification kit
Qiagen Inc.,Valencia, CA
Plasmid miniprep kit
Stratagene, La Jolla, CA
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Plasmid maxiprep purification kit
Qiagen Inc.,Valencia, CA
5. Equipment
Analytical balance
Mettler Toledo Inc., OH
Weighing scale
Denver Instruments Co., CO
Bottletop dispenser
Brinkmann Instruments Inc., NY
Cell culture incubator
Forma Scientific, MA
Centrifuge Model 228
Fisher Scientific, Pittsburgh, PA
Centrifuge 5415 C
Eppendorf Scientific Inc., NY
Centrifuge 5810 R
Eppendorf Scientific Inc., NY
Confocal laser microscope Leica TCS-SP2
Leica Microsystems Inc., PA
Dispensing Eppendorf pipetter (50 ml)
Brinkmann Instruments Inc., NY
Electrophoresis Power Supply
Life Technologies Inc., Gaithersburg, MD
Horizontal Gel Electrophoresis System
Life Technologies Inc., Gaithersburg, MD
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Inverted microscope Olympus CK40
Fisher Scientific, Pittsburgh, PA
Isotemp Incubator
Fisher Scientific, Pittsburgh, PA
Lab freezers and refrigerators
Forma Scientific, MA
Liquid Nitrogen tank
Liquid Scintillation Analyzer
Packard Instruments Co., CT
Millipore Milli-Q and Elix
Millipore Corporation, MA
Mixer (Style: 37600)
Thermolyne Corporation, IA
NapFLOW Laminar air flow unit
Fisher Scientific, Pittsburgh, PA
ORBIT Shaker
Lab-line Instruments Inc., IL
PCR Mastercycler
Eppendorf Scientific Inc., NY
pH meter AB15
Fisher Scientific, Pittsburgh, PA
Pipet-aid
Drummond Scientific Co., Broomall, PA
Pipetman (P-2, P-10, P-20, P-100, P-200, P-1000)
Mettler Toledo Company, Woburn, MA
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Polaroid Gelcam
Polaroid Corporation, Cambridge, MA
Stir plate Nuova II
Thermolyne Corporation, IA
Universal Vacuum System UVS 400
Savant Instruments Inc., NY
Vacuum pressure pump
Barnant Co., IL
UV Transilluminator M-26
UVP Inc., Upland, CA
UV-Visible Spectrophotometer DU 530
Beckman Instruments Inc., Fullerton, CA
Vertex-2 Genie
Scientific Industries Inc., NY
Water bath 180 series
Precision Scientific, Winchester, VA
Water bath Iso TEMP 205
Fisher Scientific, Pittsburgh, PA

6. Computer software
GraphPad Prism 5.0
GraphPad Software, San Diego, CA
Adobe Acrobat Reader 7.0
Adobe Systems Inc., San Jose, CA
Adobe Acrobat Writer
Adobe Systems Inc., San Jose, CA
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ChemDraw Ultra 11.0
CambridgeSoft Corporation, Cambridge, MA
Microsoft Office Word & Excel 2003
Microsoft Corporation, Seattle, WA
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B. Methodology and Procedures
1. Cell culture
COS-7 cells and N2A cells were employed for experiments requiring transient
transfection of plasmid DNA.

COS-7 cells were maintained in DMEM media

supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 units/ml
streptomycin and 20 mM L-glutamine. The N2A cell line employed in the study were
kindly provided by Dr. Margaret E. Gnegy’s laboratory, University of Michigan, MI.
The cells were grown in Opti-MEM media supplemented with 10% FBS, 100 units/ml
penicillin and 100 units/ml streptomycin.

N2A cells stably transfected with WT DAT

were cultured in Opti-MEM media supplemented with 10% FBS, 100 units/ml penicillin,
100 units/ml streptomycin

and 450 µg/ml G418.

All cell types were grown as

monolayers in 75 cm2 flasks at 37ºC and 5% CO2 and subcultured twice weekly or every
3 days. For subculturing the COS-7 cells, the exhausted media in the flask was aspirated
and the confluent adherent cells were washed once with 10 ml Hanks buffered salt
solution (HBSS).

The cells were then detached by addition of 3ml trypsin-EDTA

solution to the monolayer. The trypsin-EDTA solution was swirled to coat the monolayer
and 2 ml of the trypsin-EDTA was aspirated from the flask. The flask was then returned
to the incubator for 3 min or until the cells detached from the flask. The detached cells
were resuspended in 9 ml complete media to quench the trypsinization reaction. Two ml
of the cell suspension was transferred into a new labeled flask containing 18 ml of
complete media. The flask was capped and the cells evenly suspended by gently swirling
the flask. The flask was placed in the incubator and the cells were allowed to grow till
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the next subculture. For subculturing the N2A and WT DAT N2A cells, the exhausted
media in the flask was aspirated and the confluent adherent cells were washed with 10 ml
HBSS. To detach the cells from the flask, 3 ml of trypsin-EDTA was added and swirled
to cover the cell monolayers, and then 2 ml of the trypsin-EDTA was aspirated. When
the cells were detached from the flask, 9 ml of complete Opti-MEM media was added to
inactivate the trypsin-EDTA. The cell suspension was transferred into a 15 ml tube and
centrifuged at 1000g for 5 minutes. The supernatant was decanted and cell pellet was
resuspended in 10 ml complete Opti-MEM media. Two ml of the cell suspension was
then transferred into a new labeled flask containing 18 ml of complete fresh Opti-MEM
media. The flask was tightly capped and then gently swirled to evenly suspend the cells.
The flask was placed in the incubator and the cells were allowed to grow until the next
subculture.
2. Site-directed mutagenesis
All site-directed mutagenesis was conducted using the QuickChange mutagenesis
kit (Stratagene). rDAT in Bluescript vector was used as template for the polymerase
chain reaction (PCR)-based mutagenesis. Sense and antisense oligonucleotides were
designed to contain the desired mutations. The oligonucleotide primers were synthesized
by Operon Biotechnologies Inc., Huntsville, AL, U.S.A. Sixteen mutants were designed
and generated: Y88A, R85D, D475R, R85D/D475R, K92D, D312K, K92D/D312K,
D384A, D384N, G425I, I468C, I468A, T472A, T472K, H476A and F542A.

The

sequences of primers used for the generation of Y88A DAT were: 5’GTCTGGAGGTTTCCCGCCCTGTGCTACAAAAATG-3’ for the forward primer and
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5’-CATTTTTGTAGCACAGGGCGGGAAACCTCCAGAC-3’ for the reverse primer.
The

sequences

of

primers

designed

for

R85D

DAT

were:

5’-

CTGGCCAATGTCTGGGATTTTCCCTACCTGTGC-3’ for the forward primer and 5’GCACAGGTAGGGAAAATCCCAGACATTGGCCAG-3’ for the reverse primer. The
sequences of primers used for the generation of D475R DAT were: 5’GTCTCACACTGCTGCGCCACTTTGCAGCTGGCACA-3’ for the forward primer and
5’-TGTGCCAGCTGCAAAGTGGCGCAGCAGTGTGAAGAC-3’

for

the

reverse

primer. The primers for generating R85D DAT and D475R DAT were also employed to
generate switch mutant R85D/D475R DAT. The sequences of primers used for the
generation

of

K92D

DAT

were:

5’-

GTTTCCCTACCTGTGTGCTACGATAATGGTGGAGGTGCCTTC-3’ for the forward
primer and 5- GAAGGCACCTCCACCATTATCGTAGCACAGGTAGGGAAAC-3’ for
the reverse primer.

The sequences of primers used for the generation of D312K DAT

were: 5’-GCATCTGTGTGGATCAAAGCTGCCACCCAGGTGT-3’ for the forward
primer and 5’-CACCTGGGTGGCAGCTTTGATCCACACAGATGCCTC-3’ for the
reverse primer. The primers for generating K92D DAT and D312K DAT were also
employed to generate switch mutant K92D/D312K DAT. The sequences of primers used
for

the

generation

of

D384A

DAT

were:

5’-

CAGAGATGTGGCCACAGCTGGACCTGGGCTCATC-3’ for the forward primer and
5’-GATGAGCCCAGGTCCAGCTGTGGCCACATCTCTG-3’ for the reverse primer.
The sequences of primers used for the generation of D384N DAT were: 5’CAGAGATGTGGCCACAAATGGACCTGGGCTCATC-3’ for the forward primer and
5’-GATGAGCCCAGGTCCATTTGTGGCCACATCTCTG-3’ for the reverse primer.
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The sequences of primers used for the generation of G425I DAT were: 5’GTATCGACAGTGCAATGGGGATCATGGAGTCAGTG-3’ for the forward primer
and 5’- CACTGACTCCATGATCCCCATTGCACTGTCGATAC-3’ for the reverse
primer. The sequences of primers used for the generation of I468C DAT were: 5’GTCACCAACGGTGGCTGCTACGTCTTCACACTG-3’ for the forward primer and 5’CAGTGTGAAGACGTAGCAGCCACCGTTGGTGAC-3’ for the reverse primer. The
sequences of primers used for the generation of I468A DAT were: 5’GTCACCAACGGTGGCGCCTACGTCTTCACACTG-3’ for the forward primer and 5’CAGTGTGAAGACGTAGGCGCCACCGTTGGTGAC-3’ for the reverse primer. The
sequences of primers used for the generation of T472K DAT were: 5’GTGGCATCTACGTCTTCAAACTGCTGGACCACTTTGC-3’ for the forward primer
and 5’- GCAAAGTGGTCCAGCAGTTTGAAGACGTAGATGCCAC-3’ for the reverse
primer. The sequences of primers used for the generation of T472A DAT were: 5’GTGGCATCTACGTCTTCGCACTGCTGGACCACTTTGC-3’ for the forward primer
and 5’- GCAAAGTGGTCCAGCAGTGCGAAGACGTAGATGCCAC-3’ for the reverse
primer. The sequences of primers used for the generation of H476A DAT were: 5’GTCTTCACACTGCTGGACGCCTTTGCAGCTGGCACATC-3’ for the forward primer
and

5’-GATGTGCCAGCTGCAAAGGCGTCCAGCAGTGTGTGAAG-3’

for

the

reverse primer. The sequences of primers used for the generation of F542A DAT were:
5’-CAGCATTGTGACCGCCAGACCCCCACACTAT-3’ for the forward primer and 5’ATAGTGTGGGGGTCTGGCGGTCACAATGCTG-3’ for the reverse primer.

These

complementary primers were annealed to the template cDNA and extended with the
proofreading polymerase pfu Turbo (Stratagene) with the following PCR parameters:
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denaturation of the double stranded template DNA 30 seconds at 95ºC, annealing of the
primers to the single stranded DNA 1 minute at 55ºC and extension of the new DNA
strand 6 minutes at 68ºC for 25 cycles. Subsequently, the PCR product was digested with
Dpn I to eliminate the methylated and hemimethylated, nonmutated parental DNA
strands. The mutated cDNA was then transformed into XL1-Blue supercompetent E. coli
cells using the heat-shock method. The bacterial cell solution was then plated on agar
plates containing 50 µg/ml ampicillin and incubated overnight (~16 hours) at 37 ºC. The
following day, colonies were selected and plasmid preparation was carried out using the
Stratagene miniprep system to produce pure supercoiled plasmid DNA. Mutagenesis was
confirmed by DNA sequencing analysis of the miniprep product (University of Pittsburgh
sequencing facility).

The fragment (~1800 bp) containing the mutation in rDAT-

pBluescript was isolated by double digestion with PshAI and BsiWI restriction enzymes,
gel purified, and ligated into the PshAI/BsiWI digested rDAT-pIRES vector. The ligation
product was transformed into DH5α supercompetent cells by heat shock method and the
cells were plated on ampicillin supplemented agar plates. The agar plates were then
incubated overnight (~16 hours) at 37ºC to allow growth of bacterial colonies. A few
bacterial colonies were again selected and used to inoculate 5 ml of LB broth for 16 hours.
The plasmid DNA was then purified using the Stratagene mini-prep kit. The presence of
supercoiled plasmid DNA was verified by agarose gel electrophoresis.

Following

confirmation of successful mutagenesis by DNA sequence analysis, 200 ml LB broth was
inoculated to produce large amounts of the plasmid DNA of interest.

Plasmid

preparations were carried out using the Qiagen maxi-prep kit to produce a larger volume
of pure supercoiled plasmid DNA sufficient for transient transfection of cells. The DNA
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concentration and purity (measured as A260:A280 ratio) were estimated through UV
spectrophotometic analysis. Plasmid DNA with a ratio of greater than or equal to 1.7 was
typically used for transient transfection of mammalian cells.
3. Cell Transfections
A modification of the calcium phosphate method or the use of TransIT-LT1
reagent (Mirus, Madison, WI) was employed for transient transfection of COS 7 and
N2A cells. For the calcium phosphate method, confluent cells were subcultured in 6-well
or 24-well plates such that the monolayer would be 40 - 50% confluent when the
transfection commenced the next day. Four hours prior to transfection, the media in the
wells was replaced with fresh media.

All the reagents were filter-sterilized.

The

transfection procedure involved preparing 2 tubes, with the contents of one tube added
slowly to the other one. The first tube contained Millipore water, plasmid DNA, 10х
Tris-EDTA (TE) buffer pH 8.0 and 0.5 M CaCl2 mixed together to achieve a final amount
of DNA of 20 µg. The second tube contained 2x HEPES – buffered saline (HBS)
solution.

The contents of first tube were added to the second tube dropwise with

continuous gentle vortexing and incubated at room temperature. Soon after the DNA
complexes started forming, the mixture was pipetted up and down thrice to ensure a
uniform suspension and to reduce the particle size of the complexes. For an individual
well of the 6-well plate, 200 µl of the above mixture was added, while 100 µl of the
mixture was added to a single well of 24-well plate. The cells take up the exogenous
plasmid via endocytosis of the calcium phosphate/DNA complex. After addition of the
mixture, the plate was gently swirled to ensure uniform distribution. The following day,
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the transfection mixture in each well was replaced with fresh media. The cells were used
for the pharmacological studies 48 hours after transfection.
For the TransIT-LT1 reagent-mediated transient transfection, following the
manufacturer’s protocol, N2A cells were seeded in 24-well plates at a concentration of 1
- 3 x 105 cells/well (the monolayer would be 50 -70% confluent) approximately 24 hours
before transfection. On the day of transfection, TransIT-LT1 reagent-DNA complex was
prepared immediately before transfection. TransIT-LT1 reagent was first warmed up to
room temperature and vortexed gently before using.

For preparing the transfection

mixture for the cells in one well, 1.5 µl TransIT-LT1 reagent was added to 50 µl serumfree medium in a sterile tube and mixed by gently pipetting. Plasmid DNA (0.5 µg) was
then added to the diluted TransIT-LT1 reagent, mixed by gently pipetting and incubated
for 15 - 30 minutes at room temperature to allow complex formation.

Total volume of

the transfection mix was transferred to the cells in a single well and the plate was gently
swirled to ensure even distribution of the complexes.
pharmacological assays 48 hours after transfection.

The cells were used for
When performing transient

transfections of cells in more than one well, all the volumes were scaled up appropriately.
4. [3H]-Dopamine uptake assays
[3H]-dopamine uptake assays were conducted with cell monolayers seeded in 6well or 24-well plates.

For performing simple [3H]-dopamine uptake assays, cell

monolayers were washed 2 х 1 ml with “KRH buffer” (25 mM HEPES, pH 7.3, 125 mM
NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 5.6 mM glucose)
supplemented with 50 mM ascorbic acid (KRH/AA), and then incubated with 750 µl (654

well plate) or 375 µl (24-well plate) KRH/AA buffer (total uptake) or 10 µM mazindol
(non-specific uptake) for 10 minutes, followed by incubation with 10 nM [3H]-dopamine
for an additional 5 minutes. Uptake was quenched by washing the cell monolayers 2 х 1
ml with KRH/AA buffer. Subsequently, cells in each well were lysed with 1 ml of 1%
SDS, incubated at room temperature for 1 hour with gentle shaking. The cell lysates
were transferred into scintillation vials containing 5 ml of ScintiSafe fluid and the
incorporated radioligand was determined by employing a liquid scintillation counter. The
specific uptake was calculated as the difference between total and non-specific uptake, i.e.
uptake in the presence and absence of 10 µM mazindol.
For performing [3H]-dopamine uptake inhibition assays, the cell monolayer was
washed twice with KRH/AA buffer (2 x 1 ml), incubated with inhibitors for 10 minutes,
followed by the addition of 10 nM [3H]-dopamine for a further 5 minutes. The uptake
inhibition assays included nonradioactive DAT inhibitors at the following concentration
ranges: cocaine, 1 nM – 100 µM; benztropine, 0.1 nM – 30 µM. Uptake was quenched
by aspirating the inhibitor/radioligand solution and washing the cell monolayer 2 х 1 ml
with KRH/AA buffer. Non-specific uptake was determined by using 10 µM mazindol.
The cells in each well were then lysed by incubating with 1 ml of 1% SDS at room
temperature for 1 hour with gentle shaking.

The cell lysate was transferred into

scintillation vials containing 5 ml of ScintiSafe fluid and radioactivity was counted using
a liquid scintillation counter.

The specific uptake was calculated as the difference

between total and non-specific uptake.

The IC50 values for [3H]-dopamine uptake

inhibition were determined with GraphPad Prism 5.0.
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5. [3H]-WIN35,428 saturation binding assays
All binding assays were conducted with cells subcultured in 24-well plates. [3H]WIN35,428, an analog of cocaine, was the radioligand used in all binding assays because
it is more stable in vitro. For [3H]-WIN35,428 saturation binding assay, serial dilutions
of WIN35,428 (1 nM – 10 µM) were made in KRH/AA buffer. [3H]-WIN35,428 was
added to each dilution of drug to achieve a final concentration of approximately 1 nM for
the radioligand. Cell monolayers were washed with 2 х 1 ml KRH/AA buffer and
incubated with the mixture of [3H]-WIN35,428 and WIN35,428 for 15 minutes. The
drug solution was then aspirated and the cell monolayers were washed with 2 х 1 ml
KRH/AA buffer. Cells were lysed with 1% SDS solution and the radioactivity of the cell
lysate was determined in a scintillation counter. Bmax and Kd values for [3H]-WIN35,428
binding were determined with GraphPad Prism 5.0.
6. [3H]-WIN35,428 binding inhibition assays
All competition binding assays were conducted exactly as described for the
dopamine uptake inhibition assays except that [3H]-dopamine was replaced with 1 nM
[3H]-WIN 35,428 and cells were incubated with a mixture of radioligand and the
nonradioactive competitor for 15 minutes. Serial dilutions of the drugs to be examined
were made in KRH/AA buffer. [3H]-WIN 35,428 was added to each dilution of drug to
achieve a final concentration of 1 nM for the radioligand. The ranges of concentrations
of drugs employed were as indicated above for dopamine uptake inhibition assays:
cocaine, 1 nM – 100 µM; benztropine, 0.1 nM – 30 µM. Cell monolayers were washed
with 2 х 1 ml KRH/AA buffer and incubated with the mixture of [3H]-WIN35,428 and
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the nonradioactive competitor for 15 minutes.

The experiment was quenched by

removing the drug solution and washing the cell monolayers with 2 х 1 ml KRH/AA
buffer. Non-specific binding was assessed by using 10 µM mazindol. Cells were then
lysed with 1 ml of 1% SDS solution and incubated at room temperature for 1 hour with
gentle shaking. Cell suspensions from each well were then transferred to scintillation
vials containing 5 ml of ScintiSafe fluid and radioactivity was counted using a
scintillation counter. The Ki values were determined with GraphPad Prism 5.0 software.
7. Protein assays
COS-7 and N2A cells transiently transfected with WT or mutated DAT were used
for protein assays.

For every experiment carried out that required protein content

estimation, two wells were reserved for this purpose. The protein assays were performed
as follows: the confluent cell monolayers were washed 2 x 1 ml with PBS, cells in each
well were lysed with 0.5 ml 0.2 N NaOH solution, gently scraped with a rubber cell
scraper and incubated at 4ºC with gentle shaking for 30 min. The cell lysates were
transferred into Eppendorf tubes for storage at -20ºC or for immediate protein estimation
via Bradford assay. For each assay, carried out in duplicate, 750 µl of water was added
to 50 µl of cell lysate in a test tube and mixed gently. 200 µl of BioRad reagent was then
added to the cell solution, vortexed for 10 sec, and incubated at room temperature for 10
min. The absorbance of the protein/dye solution was measured at 595 nm using a UVvisible wavelength spectrophotometer. The concentration of protein was calculated by
interpolating the absorbance reading of the sample protein using a protein standard curve.
Bovine serum albumin (BSA; 1 mg/ml stock solution) was used as the protein standard
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for generating the standard curve. A serial dilution of the BSA stock solution in sterile
water was performed to make six different concentrations of BSA such that final
concentrations were 1, 2, 3, 4, 5 and 6 µg/ml. The initial volume for each dilution was
800 µl (e.g., for 6 µg/ml: 6 µl of 1 mg/ml BSA + 794 µl of sterile water). BioRad reagent
was then added to each test tube containing the protein dilutions, vortexed for 10 sec, and
incubated at room temperature for 10 min. The absorbance of each protein dilution was
read at 595 nm. A protein standard curve was generated using Microsoft Excel by
plotting of absorbance versus amount of protein.
8. Data analysis
Statistical significance was calculated using GraphPad Prism 5.0.

Statistical

significance between two groups was determined using a two-tail Student’s t test, while
comparison among more than two groups used one-way analysis of variance with
Newman-Keuls post hoc test.
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III. RESULTS AND DISCUSSION
A. Pharmacological characterization of DAT mutants
1. Results
Wildtype (WT) DAT and sixteen DAT mutants (R85D, D475R, R85D/D475R,
K92D, D312K, K92D/D312K, Y88A, D384A, D384N, G425I, I468C, I468A, T472A,
T472K, H476A and F542A) were first screened for their abilities to bind [3H]WIN35,428 and take up [3H]-dopamine. The mutant DATs were made by site-directed
mutagenesis and confirmed by DNA sequencing.

All DAT mutants were initially

assessed in parallel to WT DAT via one point [3H]-WIN35,428 binding and [3H]dopamine uptake assays.

Relative to WT DAT, twelve DAT mutants (R85D,

R85D/D475R, K92D, H476A, Y88A, F542A, T472K, T472A, D384A, D384N, I468C
and I468A) displayed detectable specific binding of [3H]-WIN35,428, whereas ten
mutated DAT proteins (K92D, H476A, Y88A, F542A, T472K, T472A, D384A, D384N,
I468C and I468A) displayed functional uptake of [3H]-dopamine (Fig. 12). Net binding
of [3H]-WIN35,428 was decreased (around 70% loss) or eliminated by the single R85D
or D475R mutations.

The switch mutant R85D/D475R restored net binding of the

radioligand to above WT DAT levels (Fig. 12, upper panel), while none of these three
DAT mutants displayed specific uptake of [3H]-dopamine (Fig. 12, lower panel). Net
binding of K92D DAT was decreased by around 85%, while D312K DAT and switch
mutant K92D/D312K displayed no detectable binding (Fig. 12, upper panel). Specific
uptake of [3H]-dopamine (around 15% of the WT DAT) was only observed for K92D
among these three DAT mutants (Fig. 12, lower panel). The specific binding and uptake
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was eliminated by the G425I mutation (Fig. 12). Net binding of [3H]-WIN35,428 was
similar to WT DAT at mutants H476A, Y88A, F542A, T472K, T472A, D384A, D384N
and I468A. Mutant I468C displayed decreased net binding by 80% compared to WT
DAT (Fig. 12, upper panel). T472K and I468A displayed decreased uptake ability by
30%, while 70% loss of uptake ability was observed at mutation I468C. Meanwhile,
specific uptake of [3H]-dopamine at mutants H476A, Y88A, F542A, T472A, D384A and
D384N was similar to WT DAT (Fig. 12, upper panel).
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Figure 12. Determination of [3H]-WIN35,428 specific binding and [3H]-dopamine
uptake ability by COS-7 or N2A cells expressing WT or mutant DAT proteins.
The extent of specific [3H]-WIN35,428 binding (upper panel) and [3H]-dopamine
uptake (lower panel) as a percentage of WT DAT was assessed for cells transiently
transfected with plasmid encoding mutated DATs (R85D, D475R, R85D/D475R, K92D,
D312K, K92D/D312K, Y88A, D384A, D384N, G425I, I468C, I468A, T472A, T472K,
H476A and F542A). The data represent an average of 3 separate experiments. * P <
0.05 (Student T test) relative to WT DAT.
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Mutants with detectable binding or uptake were further characterized in parallel to
WT DAT. Kd and Bmax values for [3H]-WIN35,428 binding at each DAT mutant were
derived from WIN saturation binding assays. Bmax values reflect DAT expression at the
cell surface as it has been shown that WIN 35,428 does not cross the plasma membrane
of the intact cell appreciably (Chen, Zhen et al. 2004). Relative to WT DAT, the affinity
of WIN35,428 increased 8-fold at R85D DAT and 9-fold at R85D/D475R DAT.
Measured by maximal [3H]-WIN35,428 binding (Bmax), the number of drug-accessible
R85D DAT molecules was 10 fold lower than WT, while the R85D/D475R switch
mutant was 2-fold lower than WT but 9-fold higher than R85D DAT. The binding
affinity of H476A-mutated DAT protein was not significantly different from WT DAT,
whereas the number of drug-accessible protein molecules was 3-fold lower than WT
DAT.

For the F542A, Y88A, T472A and T472K mutants, both the affinity of

WIN35,428 and the number of drug-accessible DAT molecules were similar to WT DAT.
D384A substitution decreased the affinity of WIN35,428 by 5-fold and the number of
drug-accessible DAT molecules by 13-fold. The D384N mutant displayed WT-like
affinity for WIN35,428 and no change in the number of drug-accessible binding sites.
I468C and I468A mutations did not alter the binding affinity; the numbers of drugaccessible protein molecules for these two mutants were 30-fold and 2-fold lower than
WT, respectively.
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Table 1. Affinity of WIN 35,428 at N2A neuroblastoma cells or COS 7 cells
transiently expressing DAT constructs.
Kd and Bmax values were derived from experiments incubating transiently
transfected cells with nonradioactive WIN35,428 in the presence of [3H]-WIN35,428 at
room temperature in KRH/AA buffer. Values represent the mean ± SEM from at least
three independent experiments, each conducted in duplicate determinations.

DAT Construct

WIN35,428
Kd / nM

Bmax (fmol/mg)

WT

15 ± 2.1

1799 ± 316

R85D

2.0 ± 0.6*

179 ± 49*

R85D/D475R

1.7 ± 0.5*

720 ± 138*

H476A

54 ± 14

529 ± 172*

F542A

25 ± 4.7

1900 ± 216

Y88A

17 ± 3.2

1723 ± 235

T472A

11 ± 3.2

1240 ± 56

T472K

23 ± 6.7

1355 ± 133

D384A

73 ± 6.2*

142 ± 6.1*

D384N

20 ± 2.8

1667 ± 366

I468C

19 ± 8.5

60 ± 23*

I468A

11 ± 1.9

918 ± 151*

* P < 0.05 vs. WT DAT
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Binding affinity (Ki) and dopamine uptake inhibition potency (DUIP) of cocaine
were also characterized at DAT mutants in parallel to WT DAT. The R85D mutation
increased cocaine affinity by 23-fold, while the double mutation R85D/D475R increased
cocaine affinity by 16-fold (Table 2). The DUIP of cocaine at these two mutants was not
assessed because neither displayed detectable dopamine uptake (Fig. 12).

H476A

substitution displayed WT-like affinity and DUIP of cocaine. The mutation F542A did
not alter cocaine affinity, whereas the DUIP of cocaine was decreased 4-fold at this
mutation. Cocaine affinity at mutations Y88A, T472K and T472A was similar to WT
DAT, while the DUIP of cocaine was decreased around 3-fold by these three mutations.
D384A substitution decreased both cocaine affinity and DUIP by 3-fold and 6.5-fold,
respectively; D384N mutant only affected cocaine affinity (3-fold loss). Cysteine (C)
substitution at I468 did not alter either affinity or DUIP of cocaine, while alanine (A)
displacement at this position increased cocaine affinity 1.5-fold (Table 2). The ratios of
dopamine uptake inhibition potency to binding affinity for the different DAT mutants
were also calculated (Table 2).

Ki and IC50 values for WT DAT were essentially

identical (given ratio = 1). H476A DAT displayed WT-like cocaine Ki and IC50 values).
F542A, Y88A, T472K, T472A and D384A point mutations decreased the DUIP of
cocaine 3-fold compared to the corresponding binding affinity of cocaine, whereas
D384N substitution increased DUIP of cocaine 2-fold versus the binding affinity.
Mutation at I468A decreased DUIP of cocaine by 2-fold relative to binding affinity,
while I468C displayed the same binding affinity and DUIP of cocaine (Table 2).
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Table 2. Binding affinity and DUIP of cocaine at N2A neuroblastoma cells or COS
7 cells transiently expressing DAT constructs.
Ki and IC50 values were determined from experiments incubating transiently
transfected cells with cocaine in the presence of [3H]-WIN35,428 or [3H]-dopamine at
room temperature in KRH/AA buffer. Values represent the mean ± SEM from at least
three independent experiments, each conducted in duplicate determinations. Ratios were
calculated using the IC50 values and Ki values.

DAT Construct

Cocaine
Ki / nM

IC50 / nM

DUIP (IC50)/Ki

WT

214 ± 11

251 ± 27

1

R85D

9.1 ± 1.3*

ND

ND

R85D/D475R

13.3 ± 0.2*

ND

ND

H476A

224 ± 35

312 ± 78

1

F542A

339 ± 65

1023 ± 360*

3

Y88A

210 ± 27

661 ± 60*

3

T472A

264 ± 56

869 ± 85*

3

T472K

259 ± 45

763 ± 163*

3

D384A

589 ± 16*

1631 ± 43*

3

D384N

622 ± 38*

282 ± 11

0.5

I468C

251 ± 27

314 ± 45

1

I468A

140 ± 19*

335 ± 46

2

* P < 0.05 vs. WT DAT
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Binding affinity (Ki) and DUIP of benztropine were assessed at DAT mutants in
parallel to WT DAT. The R85D mutation decreased benztropine affinity by 2.5-fold,
while the double mutation R85D/D475R decreased benztropine affinity by 10-fold (Table
3).

The DUIP of benztropine at these two mutants was not assessed because neither

displayed detectable dopamine uptake (Fig. 12). Mutants H476A, F542A and Y88A
displayed WT-like affinity and DUIP of benztropine. Benztropine affinity at mutant
T472K was not appreciably altered compared to WT DAT, while the DUIP of
benztropine was increased around 2-fold by this mutation. Alanine mutation at the same
position (T472A) displayed WT-like affinity and DUIP of benztropine.

D384A

substitution reduced benztropine affinity by 7-fold and DUIP by 5-fold, while the D384N
mutant did not significantly alter either affinity or DUIP of benztropine. The I468C
substitution did not affect the affinity or DUIP of benztropine, while the I468A mutant
increased benztropine affinity 3-fold (Table 3). The ratios of DUIP-to-binding affinity
for the different DAT mutants were also calculated (Table 3).

WT DAT displayed 2-

fold lower DUIP than affinity for benztropine (ratio = 2). The H476A mutant displayed
the same Ki and IC50 for benztropine (ratio = 1). Mutations F542A and Y88A decreased
the DUIP of benztropine 2-fold compared to the corresponding binding affinity. The
T472A substitution behaved the same as WT DAT, while the T472K mutation increased
DUIP 2-fold versus the binding affinity of benztropine. DUIP of benztropine was the
same as binding affinity at mutation D384A, whereas D384N decreased the DUIP of
benztropine 3-fold relative to the binding affinity. Mutation at I468A decreased DUIP of
benztropine by 7-fold relative to binding affinity, while I468C behaved as WT DAT
(Table 3).
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Table 3. Binding affinity and DUIP of benztropine at N2A neuroblastoma cells or
COS 7 cells transiently expressing DAT constructs.
Ki and IC50 values were assessed from experiments incubating transiently
transfected cells with benztropine in the presence of [3H]-WIN35,428 or [3H]-dopamine
at room temperature in KRH/AA buffer. Values represent the mean ± SEM from at least
three independent experiments, each conducted in duplicate determinations. Ratios were
calculated using the IC50 values and Ki values.

DAT
Construct

Benztropine
Ki / nM

WT

111 ± 17

R85D

283 ± 31*

Affinity
change
(vs. WT)

IC50 / nM

DUIP change
(vs. WT)

DUIP/Ki

210 ± 41

2

↓ 2.5

ND

ND

1168 ± 172*

↓ 10

ND

ND

H476A

144 ± 28

–

177 ± 24

–

1

F542A

88 ± 12

–

242 ± 48

–

3

Y88A

91 ± 11

–

279 ± 23

–

3

T472A

131 ± 24

–

219 ± 21

–

2

T472K

237 ± 74

↓2

123 ± 32*

↑2

0.5

D384A

823 ± 183*

↓7

970 ± 99*

↑5

1

D384N

128 ± 14

–

447 ± 88

↓2

3

I468C

65 ± 6.4

↑2

145 ± 6.4*

–

2

I468A

37 ± 2.3*

↑3

265 ± 23

–

7

R85D/D475R

* P < 0.05 vs. WT DAT
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2. Discussion
Guided by the comparative DAT model, sixteen DAT mutants were made by sitedirected mutagenesis and pharmacologically characterized via [3H]-WIN 35,428 binding
displacement and [3H]-dopamine uptake inhibition assays. The effect of disrupting and
reconstituting the potential TM 1 – TM 10 bridge on DAT expression, inhibitor
recognition and substrate uptake was addressed because the DAT R85 – D475 salt bridge
appears to line the floor of the cocaine/TCA binding pocket, and because D475 could
potentially interact with the protonated N-8 tropane nitrogen atom of cocaine. The R85D
and D475R mutants would disallow formation of the bridge; the switch mutant
R85D/D475R should permit re-establishment of the salt bridge while reversing the side
chains at these positions. Unlike the WT DAT, none of the three DAT mutants displayed
detectable uptake of [3H]-dopamine in the screening assays (Fig. 12). It is not surprising
that the DAT switch mutant would be a defective transporter due to the importance
ascribed to the analogous residues in the LeuT substrate translocation cycle (Yamashita,
Singh et al. 2005; Zhou, Zhen et al. 2007). Specific binding of the cocaine analog [3H]WIN35,428 was decreased or eliminated by the single R85D or D475R mutations, but
restored to above WT DAT levels when both positions were simultaneously mutated
(R85D/D475R) (Fig. 12). Given the observation that the number of drug-accessible
double mutant DAT molecules measured by maximal [3H]-WIN 35,428 binding (Bmax)
was 9-fold higher than R85D DAT but 2-fold lower than WT (Table 1), the
compensatory net binding increase of the DAT double mutant R85D/D475R relative to
the single mutants can largely be accounted for by partial recovery of DAT expression.
The finding that addition of a second mutation reversed the poor expression level due to
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the first mutation, suggests that an interaction between the TM 1 and TM 10 residues at
least provides protein infrastructure and stability. D475R DAT did not display sufficient
binding for Bmax determination. It was not determined whether the poor D475R DAT
binding was due to poor transporter expression, loss of affinity for WIN 35,428, or both.
The improvement of net binding at the R85D/D475R double mutant was also due to a 9fold affinity increase relative to WT DAT. Clomipramine binding was also assessed
because the R85 – D475 salt bridge is suggested to be important for TCA binding in the
DAT model. R85D displayed a Ki of 2001 ± 201 nM and the switch mutant displayed a
Ki of 2033 ± 199 nM. Relative to WT DAT (6946 ± 483 nM), the binding affinity of
both R85D DAT and R85D/D495R DAT increased 3-fold. The R85D change was solely
responsible for this affinity increase; in fact, the affinities of WIN 35,428, cocaine and
clomipramine did not differ significantly between R85D DAT and the double mutant
(Tables 1 and 2). The observation that the pharmacologic profile of clomipramine was
altered by the mutations in a manner similar to that of cocaine and its analog WIN 35,428
supports the idea of a common inhibitor binding pocket between these three inhibitors.
Benztropine diverged from this pattern, with significant affinity decreases at each
mutant (Table 3). The pharmacologic findings indicate that the TM 1 R85 residue is
probably not critical for binding of cocaine or clomipramine; in fact, reversing the side
chain charge at this position actually increased cocaine affinity. R85D and D475 side
chains may repel each other, and thus increase the width of the inhibitor binding pocket.
The enlarged binding pocket might allow cocaine to access “deeper” regions of the ligand
cavity and establish additional hydrophobic interactions that explain the affinity increase.
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The finding that mutagenesis-based disruption of the putative salt bridge did not decrease
cocaine affinity is consistent with the postulate that cocaine recognizes outward-facing
MAT conformations (Chen and Justice 1998; Loland, Desai et al. 2008). As shown in
Fig. 8, at least three conformational states are suggested to occur during the transport
process for LeuT: open-to-outside (outward facing), occluded (substrate and ion bound)
and open-to-inside (inward facing). Like LeuT, DAT undergoes similar conformational
conversions during transportation cycle. The TM 1 – TM 10 salt bridge is part of the
extracellular gate. Closing the external gate is the prerequisite for the transporter to
progress to the next transporter step.

Thus, breaking of the salt bridge via above

mentioned mutations would trap the transporter in an outward-facing conformation,
which is preferred by cocaine binding. Therefore, elimination of a potential TM 1 – TM
10 salt bridge should not compromise cocaine binding, given that the external gate is
presumably open in such a conformation. However, benztropine and cocaine appear to
recognize different DAT sites or conformations (Reith, Berfield et al. 2001; Newman and
Kulkarni 2002; Chen, Zhen et al. 2004; Ukairo, Bondi et al. 2005; Loland, Desai et al.
2008). In contrast to cocaine, benztropine is postulated to recognize the inward-facing
DAT conformation (Loland, Desai et al. 2008). The external gate would be expected to
be closed for the transporter to convert to the inward-facing conformation, so eliminating
the TM 1 – TM 10 bridge via the above mutations should impair benztropine binding.
Nevertheless, the outward-facing cocaine-recognizing DAT conformation is predictably
less dependent on the external gate TM 1 – TM 10 salt bridge.

Thus, the above

pharmacologic findings are consistent with previous study results that cocaine and
benztropine recognize different conformations. The present study along with the LeuT70

TCA crystals indicate that binding of cocaine or a TCA drug drives closure of the
external gate portion in the form of the TM 1 – TM 10 salt bridge, but formation of the
bridge is not essential for high affinity binding of these drugs.
A K92 – D312 salt bridge is also suggested in the DAT model. Thus, the effect
of disrupting and reconstituting this potential TM 1 – TM 6 bridge on DAT expression,
inhibitor recognition and substrate uptake was addressed. The K92D and D312K mutants
would disallow formation of the bridge; the double mutant K92D/D312K should permit
re-establishment of the salt bridge while reversing the side chains at these positions. The
K92D mutant displayed detectable but very low [3H]-WIN 35,428 binding and [3H]dopamine uptake, while neither the single mutant D312K nor the switch mutant
K92D/D312K displayed specific [3H]-WIN 35,428 binding or [3H]-dopamine uptake (Fig.
12). Given that K92D DAT displayed specific binding and uptake of the radioligand, the
loss of binding and uptake of the switch mutant might largely be accounted for by the
single mutant D312K. D312 may play multiple roles in the many DAT conformations
involved the substrate translocation cycle, so it is not surprising that the switch mutant
would be defective in some aspect of transport. Moreover, D313 (the counterpart of
D312 in human DAT) was suggested to be involved in cation interactions and control in
part the ability of Na+ to drive the DAT between inward-and outward-facing
conformations (Surratt, Ukairo et al. 2005). Thus, the above results are consistent with
previous findings.

However, the presence of the K92-D312 salt bridge cannot be

determined from the current data. It is not determined whether the poor DAT binding
(D312K and K92D/D312K) was due to poor transporter expression, loss of affinity for
WIN 35,428, or both.

The surface expression of these mutants could be further
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investigated via biotinylation assay. Additionally, different radiolabeled ligands such as
[3H]-mazindol and [3H]-BTCP can be employed to determine whether the poor DAT
binding was due to loss of affinity for WIN 35,428.
H476, unique to the DAT, establishes H-bond and hydrophobic interactions with
cocaine but not benztropine in the DAT model. Alanine replacement of H476 removes
any significant partial positive charge, H-bonding, side chain length and any π electron
contributions. Relative to WT DAT, a slight but not significant decrease was observed
with the net binding of H476A. The slightly reduced net binding of the H476A mutant
was probably due to the loss of DAT expression. Measured by maximal [3H]-WIN
35,428 binding, the number of drug-accessible protein molecules was 3-fold lower than
WT DAT. The loss of surface expression could be due to the decreased protein synthesis
or the decreased translocation of protein to the cell membrane.

Given that Golgi

apparatus processes and packages all proteins after their synthesis, the amount of the
target protein in the Golgi apparatus could be evaluated to determine what causes the loss
of the protein surface expression. The H476A mutant displayed WT-like affinity for
WIN35,428, cocaine and benztropine (Tables 1, 2 and 3). The DUIPs of cocaine and
benztropine were not affected by this mutation. The ratio of DUIP to binding affinity for
the mutant changed from 2 to 1, suggesting a slight difference in the behavior due to the
alanine replacement. H476 is suggested by the DAT model to differentiate cocaine and
benztropine binding.

Alanine substitution should influence cocaine binding without

changing the benztropine binding profile. However, the pharmacologic findings indicate
that the TM 10 H476 residue is probably not critical for binding of either cocaine or
benztropine. Given that the dopamine uptake level was not changed, H476 is probably
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not important to the DAT infrastructure. F542 and Y88 appear to form π-π stacking with
aromatic rings of both cocaine and benztropine aromatic groups in the DAT model. Y88
can also H-bond with the C-2 ester of cocaine. Given that alanine substitution will
remove any aromaticity and H-bonding contributions, the F542A and Y88A mutation are
supposed to eliminate the protein-inhibitor interaction and thus affect the binding of
cocaine and benztropine. Binding assays demonstrated that F542A and Y88A did not
alter the affinities for WIN, cocaine or benztropine (Tables 1, 2 and 3). Bmax values
measured at these two mutants were also similar to WT DAT (Table 1). The WT-like
binding observed at F542A DAT and Y88A DAT (Fig. 12) is consistent with the
unaltered affinity and Bmax values. The DUIP of cocaine decreased 3 to 4 fold by alanine
replacement at either of these two residues, which led to DUIP-to-binding affinity ratios
dropping 3 fold, suggesting that F542 and Y88 may play some role for cocaine’s effect
on the DAT. The DUIPs of benztropine at these two mutants were similar to WT DAT.
The pharmacologic findings indicate that the TM 1 Y88 and TM 10 F542 amino acid
residues might not interact with WIN35,428 or benztropine, or form their binding pockets.
In addition, these two residues are probably not critical for DAT infrastructure.G425 (TM
8) is conserved in MATs (DAT, SERT and NET). The analogous position in LeuT is
occupied by I359, which is important for the binding site of LeuT.

The aliphatic side

chain of leucine is cradled with a hydrophobic pocket created by side chain atoms of
V104, Y108, F253, S256, F259, S355 and I359. The complementarity of the van der
Waals surface formed by the side chain of these residues to the side chain of L-leucine is
consistent with the specificity of LeuTAa for its substrate. These amino acid residues
shape the leucine binding site and determine the substrate specificity in the eukaryotic
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homologues. For example, I359 is replaced with a smaller size amino acid glycine in
MATs to accommodate the larger substrate molecules. (Yamashita, Singh et al. 2005).
Isoleucine substitution for glycine will increase the side chain length and the potential for
hydrophobic interactions, but also the steric hindrance; moreover, the replacement may
alter the DAT binding site to some extent similar as that of LeuT. G425I displayed
neither specific uptake of [3H]-dopamine nor [3H]-WIN 35,428 binding (Fig. 12). Given
the fact that this residue is important for LeuT substrate translocation, it is not surprising
that this mutant displayed as a defective transporter. It was not determined whether the
poor G425I DAT binding was due to poor transporter expression, loss of affinity for WIN
35,428, or both. T472 directly contacts cocaine in the “gate closed” poses, and also in the
“gate open” pose for benztropine in the DAT model. Alanine replacement will shorten
the side chain and eliminate the potential for H-bonding but preserve the α-helical nature
of the transmembrane domain. Lysine substitution will lengthen the side chain and
preserve the H-bonding potential. The WIN 35,428 net binding of T472A and T472K is
similar to WT DAT (Fig. 12). The number of drug-accessible DAT molecules as well as
affinities of WIN 35,428, cocaine and benztropine did not differ from those of WT DAT
(Tables 1 - 3), supporting the observation of WT-like net binding at these two mutations.
The DUIP of cocaine was decreased around 3-fold by T472A and T472K, leading to the
increase in DUIP/Ki ratio to 3. The DUIP of benztropine for T472A was similar to WT
DAT, while 2-fold improvement resulted from the T472K mutation. With respect to this
ratio, T472A substitution behaved the same as WT DAT, while the T472K mutation
reversed the ratio from 2:1 to 1:2. The T472 (TM 10) residue is probably not important
for binding of WIN 35,428 and benztropine, from the observation of WT-like binding
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affinities for these inhibitors. The decreased DUIP of cocaine and benztropine suggests
that this residue might be involved in the substrate translocation cycle. The change in the
DUIP:binding affinity ratio for cocaine and dopamine indicates mutation-induced
differences. Intriguingly, lysine replacement affected cocaine and benztropine DUIP
differently. The three-fold loss of cocaine DUIP versus 2-fold gain of benztropine DUIP
suggests that the T472K mutant differentiates cocaine and benztropine. In another words,
the increase of the side chain length via lysine substitution decreased cocaine’s DUIP,
while the DUIP of benztropine improved by this substitution. Additionally, this finding
is consistent with the postulate that cocaine and benztropine recognize different DAT
sites or conformations (Reith, Berfield et al. 2001; Newman and Kulkarni 2002; Chen,
Zhen et al. 2004; Ukairo, Bondi et al. 2005; Loland, Desai et al. 2008). Cocaine appears
to recognize outward-facing MAT conformations, while benztropine is postulated to
recognize the inward-facing DAT conformation (Chen and Justice 1998; Loland, Desai et
al. 2008).

T472K mutant might play some role to trap the transporter in the inward-

facing conformation, which is recognized by benztropine.D384 (TM 8) contributes to
cocaine and benztropine binding in the “gate closed” state. Alanine substitution will
remove charge and H-bonding potential, while asparagine replacement eliminates the
negative charge of aspartic acid but retains the side chain length and H-bond potential. A
mild decrease of the WIN 35,428 net binding was found with D384A DAT (Fig. 12),
which is largely accounted for by the loss of WIN binding affinity and lower Bmax value
(Table 1). D384N displayed WT-like WIN affinity and Bmax (Table 1). The D384A
substitution decreased cocaine affinity 3-fold and DUIP 6-fold, while the D384N mutant
only impaired cocaine affinity by 3-fold (Table 2). Thus, the 3:1 DUIP:binding affinity
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ratio for D384A versus 1:2 for D384N suggests different DAT behavior as a function of
the substitution. Moreover, alanine substitution decreased benztropine affinity by 7-fold
and DUIP by 5-fold, while the asparagine mutant did not alter either affinity or DUIP of
benztropine (Table 3). The ratio of DUIP/Ki for benztropine was 1 for D384A and 3 for
D384N, relative to 2 for WT DAT.
affinity (Appendix 1, Fig 22).

D384A also displayed WT-like clomipramine

The pharmacological findings suggest that D384 is

probably important for cocaine and benztropine binding to DAT, while the residue might
not be crucial for DAT infrastructure given that D384N did not affect the DUIP of either
cocaine or benztropine. Given that the clomipramine affinity was not altered by alanine
mutation, D384 might not be involved in the clomipramine binding (neither interact with
clomipramine nor form its binding pocket). WIN binding was affected by alanine but not
asparagine substitution, which is different from a previous report that D384N hDAT
sustained a 4 to 5 fold loss of WIN affinity (Loland, Norregaard et al. 1999). Asparagine
retained the side chain length and H-bonding potential of aspartic acid without bearing
the negative charge, indicating that the negative charge itself may be not critical for WIN
binding. H-bonding and side chain length might be important for WIN binding, based on
the difference between N and A (compared to asparagine, alanine decreases the side
chain length and eliminates H-bond potential). It was proposed that WIN binding would
be same as cocaine binding at the mutants because WIN is the analog of cocaine.
However, the D384N mutation only affected cocaine affinity, implying that binding sites
of cocaine and WIN might be slightly different. Cocaine affinity was altered similarly at
D384A and D384N mutations, indicating that the negative charge of D384 might be
important for cocaine binding (D384 may potentially interact with the protonated N-8
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tropane nitrogen atom of cocaine). Taking the above findings together, the orientation of
WIN in the binding site might be different from cocaine in that the protonated nitrogen
atom of WIN is not within the reach of D384. Therefore, WIN might interact with the
DAT protein through H-bonding and hydrophobic interactions, while cocaine interacts
with the DAT mainly through ionic pairing.

Benztropine binding and DUIP were

affected by the D384A but not D384N mutation, indicating that H-bonding and
hydrophobic interactions might be important for the recognition of benztropine.
The TM 10 I468 residue contributes to binding sites for cocaine and benztropine
in the “gate closed” state. Alanine substitution will shorten the side chain length and
decrease side chain bulk, while replacement with cysteine will shorten the side chain
length and add H-bonding potential.

The I468C mutation markedly decreased net

binding (Fig. 12), largely due to the loss of DAT expression (30-fold decrease in Bmax).
WIN affinity was same as WT DAT (Table 1). I468A displayed WT-like affinity to WIN
and a 2-fold loss of binding sites (Table 1). Cysteine substitution at I468 did not alter
either the affinity or DUIP of cocaine, while alanine displacement at this position slightly
increased cocaine affinity 1.5-fold (Table 2). H-bonding might not form with I468C and
cocaine, given the fact that cocaine affinity was not changed by this substitution. Based
on the observation that I468A did not appreciably change cocaine affinity, the side chain
size and length is probably not important for cocaine binding. I468C substitution did not
affect DUIP or affinity of benztropine, while the I468A mutant increased benztropine
affinity 3-fold (Table 3). The increase of benztropine affinity is probably due to the
decreased size of the side chain. The pharmacological findings indicate that the size of
side chain is probably critical for binding of benztropine. The less bulky alanine side
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chain seems to allow benztropine to access “deeper” regions of the ligand cavity and
establish additional interactions that explain the affinity increase.
By and large, pharmacological feedback from the mutagenesis study confirmed
some of the suggestion from the DAT model, which is encouraging, that the comparative
DAT model is valid to some extent and could be further used for ligand docking and
virtual screening. Some mutants displayed a WT-like profile, suggesting that the DAT
model needs to be refined at these positions. However, this is still valuable information
in elucidating the binding sites and refining the DAT model.

With the reliable

information of ligand binding sites, novel compounds that bind to DAT could be
designed and/or discovered as antiaddiction medications and therapies to treat other DAmediated disorders such as depression, Parkinson’s disease, anxiety, narcolepsy and
chronic pain.

Overall, site-directed mutagenesis and pharmacological assays could

illuminate the role of different amino acid residue in DAT, and help to validate and refine
the DAT model for elucidating the binding sites of different ligands, finally aid the
process for novel drug design and discover.
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B. Pharmacological characterization of analogs of classic non-tropane DAT
inhibitors
1. Results
The purpose of present pharmacological study of non-tropane-based DAT ligands
is to find high affinity candidate compounds that could be further radiolabeled and used
in the subsequent crosslinking and proteolysis assays to identify the binding pocket of
DAT.
DAT binding affinity and dopamine uptake inhibition potency (DUIP) for various
non-tropane analogs were assessed via [3H]-WIN35,428 displacement and [3H]-dopamine
uptake inhibition assays, respectively, in N2A neuroblastoma cells stably expressing
wild-type hDAT.

The analogs tested were based on the non-tropane drugs (±)-

pyrovalerone, (±)-bupropion, modafinil and (±)-methylphenidate.
(±)-SADU 2-110B, a pyrovalerone analog (benzyl group substitution for the
propyl group), decreased DAT binding affinity 60-fold relative to the 8 nM Ki value for
pyrovalerone (Lapinsky, Aggarwal et al. 2009); the DUIP was not altered by the
5modification (Fig. 13, Table 4). Increased steric hindrance by the addition of the phenyl
ring might be the reason for the significant loss of DAT binding affinity. To determine
whether the steric hindrance is important for binding affinity, larger alkyl groups, such as
ethyl, propyl and butyl could be introduced to this position. The bupropion analog (±)SADU 2-174 (3-iodo-4-azido substitution) decreased DAT binding affinity 4-fold
relative to bupropion (Ki = 441 nM; (Lapinsky, Aggarwal et al. 2009). The addition of
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the azido group might account for the loss of DAT binding affinity. The binding affinity
of (±)-SADU 3-3 (hydrochloride salt of SADU 2-174) decreased 10-fold (Ki around 4.5
µM derived from two experiments; Fig. 13, Table 4). Modafinil, an analeptic drug, is
used for the treatment of narcolepsy. It binds to DAT with affinity around 1 µM and
DUIP around 8 µM (Appendix 2, Fig 23). Modafinil can partially displace cocaine from
DAT at the concentration of 10 µM (Appendix 2, Fig 24). DJLDU 2-95, an analog of
modafinil, increased binding affinity and DUIP by 10-fold and 34-fold, respectively (Fig.
13, Table 4). The substituted piperazine might help the drug incorporate with DAT
protein better than the original amide group and thus lead to the augmentation of binding
affinity and DUIP.

Figure 13. Chemical structures of non-tropane based compounds and their analogs.
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Table 4. DAT binding affinities and dopamine uptake inhibition potencies (DUIPs)
of non-tropane based DAT ligands at hDAT N2A neuroblastoma cells.
Ki and IC50 values were derived from experiments incubating WT hDAT N2A
cells with nonradioactive DAT ligands in the presence of [3H]-WIN35,428 or [3H]dopamine at room temperature in KRH/AA buffer. Values represent the mean ± SEM
from at least three independent experiments, each conducted in duplicate determinations.

DAT Binding

DUIP

(Ki/nM)

(IC50/nM)

480 ± 99

1366 ± 153

1775 ± 381

-

Hydrochloride salt of (±) SADU 2-174

5087, 4023

-

Modafinil

1548 ± 357

8144 ± 927

161 ± 44a

236 ± 54b

Compound

(±) SADU 2-110B
(±) SADU 2-174
(±) SADU 3-3

DJLDU 2-95
a

P<0.05 vs. Ki of modafinil; b P<0.05 vs. IC50 of modafinil
Racemic threo-methylphenidate ((±)-1) and its analogs (2-18) were assessed via

[3H]-WIN35,428 displacement and [3H]-dopamine uptake inhibition assays, respectively,
in N2A neuroblastoma cells stably expressing wild-type hDAT. DAT binding affinity
and DUIP were not altered by hydroxymethyl substitution at the R2 position and benzyl
substitution at the R3 position ((±)-2). Further modification at R3 with a 3-iodo-4-azido
benzyl group ((±)-3) failed to display a consistent DAT binding affinity due to the poor
solubility of this compound (Fig. 14, Table 5).
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Methyl substitution at R3 ((±)-4)

decreased binding affinity 3-fold and DUIP 1.5-fold, suggesting that the methyl group is
mildly tolerated at this position (Fig. 14, Table 5).

DAT affinity was improved

approximately 5-fold upon substituting the 3-position of methylphenidate’s aromatic ring
with iodine ((±)-5), further supporting the observation that halogens are tolerated at this
position (Deutsch, Shi et al. 1996) and suggesting an anchoring position for

125

I as a

radiotracer tag. The DUIP of 3-iodo-methylphenidate ((±)-5) was also improved by 10fold (Fig. 14, Table 5). The DAT binding affinity of 4-iodo-methylphenidate (iodine
substitution at the para position of methylphenidate’s aromatic ring) ((±)-12) was
approximately 2-fold higher than methylphenidate, while the DUIP of this compound
increased 14-fold (Fig. 14, Table 5). DAT binding affinity and DUIP were diminished
(46-fold and 4-fold, respectively) by 4-iodo-phenyl substitution at R3 ((±)-6). Affinity
was even worse (130-fold loss vs. 1) with compound (±)-7 bearing a further modification
of 3-iodo-4-azido-benzyl group at R3, suggesting that the presence of a halogen and an
azo group on the R3 aromatic ring might not be tolerated. Compound (±)-8, a modified
version of (±)-5 that adds a 4-azido-benzyl substitution at the R3 position, decreased
binding affinity by 26-fold as well as 12-fold for DUIP (Fig. 14, Table 5). Affinity was
5-fold lower than methylphenidate by propenyl substitution at R2 ((±)-9), whereas DUIP
was decreased 2-fold by this modification. Ethyne substitution at the 3-position of
methylphenidate’s aromatic ring ((±)-10) improved binding affinity 7-fold and DUIP 40fold. DAT binding affinity was reduced 23-fold by the addition of 4-azido-phenyl group
to the methyl ester group at position R2 ((±)-11) based on the 3-iodo-methylphenidate
structure. The 4-azido-benzyl substitution at the R3 position of 4-iodo-methylphenidate
((±)-13) decreased affinity 14-fold, whereas DUIP was decreased 18-fold. Compound
82

(±)-14, bearing a 3-azido-benzyl group at the R3 position of 3-iodo-methylphenidate,
impaired binding affinity 82-fold as well as decreasing DUIP by 30-fold.

Binding

affinity was 21-fold lower with 2-azido-benzyl replacement at the R3 position of 4-iodomethylphenidate ((±)-15), while DUIP was also decreased 8-fold. The 3-iodo-4-azidobenzyl substitution at R3 ((±)-16) impaired binding affinity and DUIP by 76-fold and 49fold, respectively. The 2-azido-benzyl substitution at R3 of 3-iodo-methylphenidate ((±)17) decreased affinity 44-fold, whereas DUIP was diminished 17-fold.

A 110-fold

decrease of binding affinity was observed upon substituting the 4-position of
methylphenidate’s aromatic ring with iodine and an N-3-azido-benzyl substitution ((±)18), while 49-fold loss of DUIP was observed (Fig. 14, Table 5).
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Figure 14. Chemical structures of methylphenidate (1) and its analogs (2-18).
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Table 5. DAT binding affinities and dopamine uptake inhibition potencies of
methylphenidate-based DAT ligands at hDAT N2A neuroblastoma cells.
Ki and IC50 values were derived from experiments incubating hDAT N2A cells
with nonradioactive DAT ligands in the presence of [3H]-WIN35,428 or [3H]-dopamine
at room temperature in KRH/AA buffer. Values represent the mean ± SEM from at least
three independent experiments, each conducted in duplicate determinations.
Binding to DAT

DUIP

(Ki/nM)

(IC50/nM)

1(Methylphenidate)

25 ± 1*

156 ± 58*

2

28 ± 7

107 ± 22

3

177.3, 878.8, 860.8, 979,
1108 (solubility problem)

-

4

70 ± 8a

238 ± 14c

5

4.5 ± 1a

14 ± 5b

6

1147 ± 241a

663 ± 40b,c

7

3243 ± 804

-

8

658 ± 70a

1828 ± 261b,c

9

123 ± 7.9a

358 ± 11b,c

10

3.5 ± 0.1a

3.9 ± 1.1b

11

586 ± 61a

-

12

14 ± 3a,*

11 ± 2b

13

363 ± 28a,*

2764 ± 196b,c

14

2056 ± 73a

4627 ± 238b,c

15

517 ± 65a

1232 ± 70b,c

16

1911 ± 271a

7599 ± 106b,c

17

1112 ± 163a

2696 ± 178b,c

18

2754 ± 169a

7966 ± 348b,c

Compound

a

P<0.05 vs. Ki of (+)-1, threo-methylphenidate; bP<0.05 vs. IC50 of (+)-1, threomethylphenidate; cP<0.05 vs. its corresponding Ki.* Experiments done by Yurong Huang.
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2. Discussion
Analogs of non-tropane based drugs (pyrovalerone, bupropion, modafinil and
methylphenidate) were tested in this study to help to find the potential photoaffinity
ligands used for crosslinking and proteolysis studies. A dramatic loss (60-fold) of DAT
binding affinity was found for the pyrovalerone analog, suggesting that substituting the
propyl group of pyrovalerone with a benzyl group appears to increase steric hindrance
and thus inhibit the interaction between the drug and DAT protein. Addition of an azido
group to bupropion’s aromatic ring appears to modestly impair the drug-DAT interaction
(4-fold affinity decrease). In addition, iodine replacement of chlorine might also affect
drug recognition by the DAT protein. DJLDU 2-95, an analog of modafinil, increased
binding affinity and DUIP by 10-fold and 34-fold, respectively (Fig. 13, Table 4). Two
cation centers generated by the addition of piperazine may form an ionic bond with the
DAT protein. In addition, the side chain length, hydrophobic and π-stacking potential,
and flexibility are significantly increased by the substituted piperazine of the modafinil
analog. Those modifications appear to improve the incorporation of the drug in the DAT
protein; e.g., the more flexible side chain may allow the drug to dock deeper into the
primary substrate/inhibitor pocket). The low nanomolar affinity suggests that DJLDU 295 could be further modified (addition of azido and iodo groups) to develop a potential
photoaffinity probe.

Modafinil itself was tested with some of the DAT mutants

(Appendix 2, Table 9 and Fig 25). In contrast to WT DAT, the binding affinity of R85D
decreased 5-fold, suggesting that R85 might be involved in the modafinil binding pocket
(either interacting with modafinil or forming the binding pocket). To determine whether
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the binding site of analog DJLDU 2-95 is different from modafinil as proposed, DJLDU
2-95 could be further investigated with mutated DAT proteins.
A series of methylphenidate analogs (2-18) were assessed in parallel to racemic
threo-methylphenidate ((±)-1) via [3H]-WIN35,428 displacement and [3H]-dopamine
uptake assays. Remarkable improvement of binding affinity (7-fold) and DUIP (40-fold)
was observed for (±)-10, bearing an ethyne substitution at the 3-position of
methylphenidate’s aromatic ring, suggesting that the modification is tolerated at this
position. Iodine substitution ((±)-5) at the same position was also observed to increased
binding affinity and DUIP by 5-fold and 10-fold, respectively, supporting the observation
that halogens are tolerated at this position (Deutsch, Shi et al. 1996; Misra, Shi et al.
2010). Iodine substitution at the 4-position of methylphenidate’s aromatic ring increased
binding affinity 2-fold and DUIP 14-fold as well. A previous study with the same
substitution displayed a 6-fold affinity increase using [3H]-WIN35,428 displacement
assay (Misra, Shi et al. 2010). Several analogs were designed and synthesized based on
3-iodo-methylphenidate or 4-iodomethylphenidate. The 4-azido-phenyl substitution at R2
of 3-iodo-methylphenidate displayed affinity in the nanomolar range (Ki = 586 ± 61 nM).
Substituting the piperidine nitrogen of these iodo-methylphenidates with a N-benzyl
group bearing an aromatic azo group resulted in a significant decrease in DAT binding
affinity (~14-fold to 110-fold lower binding affinity than methylphenidate) as well as
DUIP (~ 8-fold to 49-fold lower than that of methylphenidate). N-(p-azido-benzyl)-4iodomethylphenidate ((+)-13) displayed the highest DAT affinity (Ki = 363 ± 28 nM) out
of the series of hybrid compounds. DAT binding affinity displayed differently with
respect to the position of the azide group on the N-benzyl aromatic ring. Substitution of
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the azide at the para position decreased binding affinity by 14-fold (3-iodomethylphenidate) and 26-fold (4-iodo-methylphenidate), while the ortho position
substitution resulted in a greater loss of affinity (21-fold for 3-iodo-methylphenidate and
44-fold for 4-iodo-methylphenidate). However, substitution of the azide at the meta
position resulted in a much greater decrease in DAT binding affinity (110 and 82-fold
lower binding affinity than methylphenidate). Thus, these designed azido-N-benzyliodo-methylphenidates behaved unlike previously reported methylphenidates in which Nbenzyl substitution either increased or retained DAT affinity (Misra, Shi et al. 2010).
There was no obvious advantage in terms of DAT binding affinity associated with the
position of the iodine in these hybrid analogs (average Ki: 3-iodo compounds = 1280 nM;
4-iodo compounds = 1210 nM).
With respect to identifying candidate probes for a photoaffinity labeling study,
ideal compounds are those that retain similar bioactivity as the parent compound.
However, compounds with as much as 1000-fold lower activity can still be useful
(Dorman and Prestwich 2000).

Therefore, compound (±)-13 (Ki = 363 ± 28 nM),

displaying the highest DAT affinity out of the series of methylphenidate analogs, was
further developed into a potential DAT photoaffinity probe. The radiolabeled 125I-(±)-13
was synthesized by the laboratory of Dr. John Lever (Univ. Missouri).

The

radioiodinated version was assessed via photoaffinity labeling experiments (Dr. Roxanne
Vaughan’s group, Univ. North Dakota).

The radiolabeled analog was successfully

incorporated into the DAT, and co-incubation of

125

I-(±)-13 with nonradioactive D-(+)-

methylphenidate or (–)-2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane (β-CFT, WIN35,428, a cocaine analog) blocked DAT labeling (Fig. 15). The successful incorporation
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of the radiolabeled analog indicates that the analog is binding to the DAT protein. In
addition, the displacement binding implies that the radiolabeled analog is binding to the
same binding pocket as cocaine and methylphenidate. In aim 1, the mutagenesis studies
were based on the predicted binding pocket of cocaine and benztropine. The results
suggest that the DAT region interacting with the analog is same as the binding pocket
predicted from aim 1. Therefore, aim 2 partially supports aim 1. To determine which
amino acid is involved in the binding of this photoaffinity probe, the covalent interaction
between

125

I-(±)-13 and DAT protein will be further explored by DAT proteolysis and

identification of the drug-bound DAT fragment via western blotting.

Docking of

compound (±)-13 with the DAT model will then indicate the most likely residue(s) for
the point of crosslink, and these targets will be addressed via site-directed mutagenesis.
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Figure 15. Photoaffinity labeling of DAT with [125I]-(+)-13.
Rat striatal membranes were photoaffinity labeled with 30 nM [125I]-(+)-13 in the
absence or presence of 10 µM or 100 µM β-CFT or D-MPH. Membranes were
solubilized and DATs were immunoprecipitated followed by analysis by SDS-PAGE and
autoradiography. The relevant portion of a representative autoradiograph is pictured
followed by a histogram that quantitates relative band intensities. Mean ± S.E. of three
independent experiments is shown; ***, p < 0.001 vs. control. Experiments conducted by
Dr. Roxanne Vaughan’s group.
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C. Pharmacological characterization of novel DAT ligands identified through in
silico screening using the DAT model
1. Results
Ten virtual screening (VS) “hit” compounds (coded MI-11 through MI-20) were
selected and purchased based on their optimal score, predicted pKi values, visual binding
site fitting, availability and price (Fig. 16). Initially, 10 µM of each VS “hit” compound
was assessed via [3H]-WIN 35,428 displacement and [3H]-dopamine uptake inhibition
assays in N2A neuroblastoma cells stably expressing wild type (WT) hDAT. The [3H]WIN 35,428 binding displacement assays demonstrated that MI-15, MI-17 and MI-20
were able to block [3H]-WIN 35,428 binding in a statistically significant fashion. In this
binding screen, MI-17 inhibition approached the potency of the positive control inhibitor
mazindol, which possesses low nanomolar DAT affinity. The [3H]-dopamine uptake
inhibition screening assay indicated that MI-15, MI-17 and MI-20 appreciably inhibited
dopamine uptake (Fig. 17). With hDAT N2A cells, MI-15 displayed a DAT affinity of
801 nM as measured by WIN 35,428 displacement and a DUIP of 1876 nM. MI-17
displayed 1298 nM for DAT affinity and 3774 nM for DUIP. MI-20 displayed a DAT
affinity and DUIP of 1351 nM and 4133 nM, respectively (Fig. 18, Table 6).
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Chemical structures of virtual screening “hit” compounds employed
3
in [ H]-WIN35,428 displacement and [3H]-dopamine uptake inhibition assays.
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Figure 17. Initial DAT binding affinity and dopamine uptake inhibition screening
for MI-11 to MI-20 at N2A neuroblastoma cells stably expressing WT hDAT.
DAT binding affinities were assessed via [3H]-WIN35,428 displacement when
MI-11 to MI-20 (10 µM) were co-incubated (upper panel). [3H]-dopamine uptake
inhibition was assessed by pre-incubation with MI-11 to MI-20 (10 µM) (lower panel).
The data represent an average of at least 3 separate experiments.
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Figure 18. MI-15, MI-17 and MI-20 DAT binding affinity and dopamine uptake
inhibition potency in N2A cells.
Inhibition of [3H]-WIN35,428 binding (left panels) and inhibition of [3H]dopamine uptake (right panels) at N2A neuroblastoma cells stably expressing WT hDAT
(n = 3 for each assay).
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Table 6. DAT binding affinities and dopamine uptake inhibition potencies of MI
hits at hDAT N2A neuroblastoma cells.
Ki and IC50 values were derived from experiments incubating hDAT N2A cells
with nonradioactive DAT ligands in the presence of [3H]-WIN35,428 or [3H]-dopamine
at room temperature in KRH/AA buffer. Values represent the mean ± SEM from three
independent experiments, each conducted in duplicate determinations.

Binding to DAT

DUIP

(Ki/nM)

(IC50/nM)

MI-15

801 ± 91

1876 ± 480

MI-17

1298 ± 36

3774 ± 407

MI-20

1351 ± 163

4133 ± 560

Compound
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Several drugs are known to exert their effects by modulating more than one
neurotransmitters in the brain, such as cocaine and amphetamine. Cocaine can bind to all
three monoamine transporters (DAT, SERT and NET) and inhibit the reuptake of the
corresponding neurotransmitters (dopamine, serotonin and norepinephrine). Additionally,
SERT has been considered as a key molecular target for clinically effective
antidepressants including the tricyclic antidepressants (TCAs), the serotonin and
norepinephrine reuptake inhibitors (SNRIs) and the selective serotonin reuptake
inhibitors (SSRIs) (Henry, Defelice et al. 2006). Therefore, it is of interest to know
whether those VS “hit” compounds have any effect on other monoamine transporters. To
investigate VS “hit” compound binding and substrate uptake inhibition at the human
serotonin transporter (hSERT), human embryonic kidney (HEK) cells stably transfected
with SERT cDNAs were employed. The cocaine analog [125I]-RTI-55 served as the
binding radioligand, a compound similar to WIN 35,428 in DAT affinity and identical to
WIN 35,428 except for a para- iodine-for-fluorine substitution on the C-3 phenyl ring.
Substrate uptake was monitored with [3H]-serotonin. The screening tests indicated that
only MI-17 was able to block [125I]-RTI-55 binding and inhibit [3H]-serotonin uptake.
MI-17 inhibition approached the potency of the positive control inhibitor paroxetine,
which possesses low nM SERT affinity (Fig. 19). Interestingly, MI-17 affinity at hSERT
was 4.5-fold higher than at hDAT, and serotonin uptake inhibition potency (SUIP) was
similar to that at hDAT (Table 7). MI-17 was then employed as the lead compound to
develop compounds with better selectivity to SERT, which could be further developed as
new SSRIs.

Based on the structure of MI-17, an analog modified predicted to be

favorable for hSERT binding was synthesized by the Lapinsky lab (DJLDU 3-79) and
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was tested at hDAT and hSERT. As expected, DAT binding affinity was not appreciably
altered (1.6 fold lower) compared to MI-17, while DUIP was not altered by the
modification. However, a 13-fold increase in SERT binding affinity was observed with
the MI-17 analog DJLDU 3-79 (Table 7). Thus, the modification of MI-17 succeeded in
improving binding affinity to hSERT without change DAT binding affinity. In other
words, SERT/DAT selectivity was improved by this modification, as intended.
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Figure 19. Initial SERT binding affinity and serotonin uptake inhibition screening
for MI-11 to MI-20 at HEK cells stably expressing WT hSERT.
SERT binding affinities were assessed via [125I]-RTI-55 displacement when MI11 to MI-20 (10 µM) were co-incubated (upper panel). [3H]-serotonin uptake inhibition
was assessed by pre-incubation with MI-11 to MI-20 (10 µM) (lower panel). The data
represent an average of at least 3 separate experiments.
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Table 7. Binding and substrate uptake inhibition of MI-17 and its analog (DJLDU
3-79) at hDAT-N2A and HEK-hSERT cells.
Ki and IC50 values were derived from experiments incubating cells with MI-17 or
MI-17 analog in the presence of radioligand in N2A neuroblastoma cells stably
expressing WT hDAT ([3H]-WIN35,428 or [3H]-dopamine) or HEK cells stably
expressing WT hSERT ([125I]-RTI-55 or [3H]-serotonin). Values represent the mean ±
SEM from three independent experiments, each conducted in duplicate determinations.

DJLDU 3-79

MI-17

O
Cl
N

OH

HO

DAT binding (Ki/nM)

1298 ± 36

2129 ± 177

DUIP (IC50/nM)

3774 ± 407

3436 ± 245

SERT binding (Ki/nM)

284 ± 66

22 ± 13a

SUIP (IC50/nM)

1167 ± 26

_

a

Experiments conducted by Dr. Tammy Nolan.
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In addition to MI-11 to MI-20, another series of VS “hit” compounds (MI-1 to
MI-10) were tested previously. MI-4 (Fig. 16), displaying the highest DAT affinity (6
µM), was identified out of this series of VS hit. Moreover, MI-4 displayed a DUIP of 28
µM. Given that the DUIP of MI-4 was so weak as to be negligible, the possibility that
MI-4 could reduce cocaine DUIP and thus antagonize the actions of cocaine was
addressed. Cocaine inhibition of [3H]-dopamine uptake was assessed using the hDAT
N2A cell line, in the absence and presence of 10 µM MI-4. The DUIP IC50 value of
cocaine alone (291 ± 56 nM) was increased approximately 3-fold (845 ± 118 nM) in the
presence of MI-4 (Fig. 20). Thus, MI-4 can partially displace the classic DAT inhibitor
cocaine at a concentration (10 µM) that lacks appreciable inhibition of dopamine uptake.
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Figure 20. MI-4 decreases the DUIP of cocaine.
The inhibition of [3H]-dopamine uptake by cocaine in the absence (○) or presence
(●) of 10 µM MI-4 at hDAT/N2A neuroblastoma cells (n = 3 experiments). Reformatted
with permission from ACS Chemical Neuroscience from Indarte et al., 2010.
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MI-4 docking with the DAT comparative model suggests a series of binding
modes. The best-scoring (Affinity dG) binding mode of MI-4 indicates an array of
interactions within the vestibular binding pocket (Fig. 21). The benzylic hydroxyl group
of MI-4 appears to establish H-bonds with Arg85 (TM 1) and Asp475 (TM 10). This
aromatic ring is also within reach of Tyr88, providing the potential for π-π aromatic
stacking. Asp384 in the fourth extracellular loop (ECL4a-4b) may also H-bond with a
hydroxyl group of MI-4. The charged amine from the benzylpiperidine is indicated to be
able to form an H-bond with Thr472 (TM 10) in the current pose.
As suggested by the docking results, three mutated DAT proteins (R85D,
R85D/D475R and D384A) were tested with MI-4 via [3H]-WIN 35,428 binding
displacement assays.

MI-4 displayed a DAT binding affinity of 4.1 µM, while R85D

mutation decreased affinity by 4-fold. WT-like binding affinities were observed at the
R85D/D475R and D384A DAT mutants. In addition, other DAT mutants were tested
with MI-4 via 3-point [3H]-WIN 35,428 binding displacement assays (three
concentrations of MI-4 were applied: 0.5 µM, 2 µM and 10 µM) (Appendix 2, Fig 25).
Some mutants displayed differently relative to the WT DAT, such as Y88A, T472A, and
I468A. WT-like binding affinity of MI-4 was observed at T472A (Appendix 5). Further
characterization is needed to determine MI-4 binding affinity at other DAT mutants.
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Figure 21. MI-4 docking in the DAT model
Optimal positioning of MI-4 in the DAT vestibular pocket is depicted by the topranked pose generated by MOE-Dock 2007.
For reference, the primary
substrate/inhibitor pocket (below the vestibular pocket) is indicated by superpositions of
docked dopamine (green) and the analogous position of leucine (orange, sticks) in LeuT.
DAT vestibular pocket side chains (atom colored) within 5 Å of the docked MI-4
molecule (yellow / atom colored) are shown. Intermolecular H-bond interactions are
indicated (pink dashed lines). Pose generated by Dr. Martin Indarte. Reprinted with
permission from ACS Chemical Neuroscience from Indarte et al., 2010.
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Table 8. Affinity of MI-4 at N2A neuroblastoma cells transiently expressing DAT
constructs.
Ki values were derived from experiments incubating transiently transfected cells
with MI-4 in the presence of [3H]-WIN35,428 at room temperature in KRH/AA buffer.
Values represent the mean ± SEM from four independent experiments, each conducted in
duplicate determinations.
DAT Construct

DAT binding affinity
(Ki/µM)

WT

4.1 ± 0.1

R85D

16 ± 2.4*

R85D/D475R

5.9 ± 1.4

D384A

5.2 ± 1.0

* P < 0.05 vs. WT DAT

104

2. Discussion
In the present study, ten VS “hit” compounds were pharmacologically
characterized via [3H]-WIN 35,428 displacement and [3H]-dopamine uptake inhibition
assays.

MI-15, MI-17 and MI-20 displayed appreciable inhibition on WIN 35,428

binding and dopamine uptake in initial screening assays (Fig. 17). DAT affinity of these
compounds was approximately 1 µM, and DUIP was approximately 3-fold lower than
affinity (Fig. 18, Table 6), suggesting that the in vitro concentration needed to block
dopamine uptake is approximately 3 times higher than the concentration needed to inhibit
binding of WIN (a cocaine analog). This finding implies that these novel compounds
obtained by VS are capable of antagonizing a cocaine analog without appreciably
disrupting the dopamine uptake function of the DAT. In addition, to validate the model
and the virtual screening method, 10 non-hit compounds were purchased and tested
(Appendix 3). Most compounds failed to show any inhibition on WIN 35,428 binding
and dopamine uptake, only one compound displayed moderate inhibition on WIN 35,428
binding and dopamine uptake. These VS hits were also assessed with the SERT; only
MI-17 displayed appreciable inhibition of RTI-55 binding and serotonin uptake (Fig. 19).
In addition, MI-17 displayed an affinity at hSERT 4.5-fold higher than at hDAT. The
modified MI-17 analog remarkably increased SERT binding affinity (13-fold), and thus
improved the drug selectivity (Table 7).
Previously identified VS hit MI-4 interfered with cocaine binding at the DAT to
the extent that cocaine DUIP was reduced 3-fold (Fig. 20). Based on the suggestion of
the docking results (Fig. 21), MI-4 affinity at mutated DAT proteins (R85D,
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R85D/D475R and D384A) was tested (Table 8). The change of the charge and side chain
length might account for the observation of 4-fold loss of binding affinity at R85D DAT.
WT-like affinity at the double mutant suggests that alterations by the single mutation
were compensated for by the switch substitution, supporting the existence of the
R85/D475 salt bridge. D384 is indicated to establish H-bonding with a hydroxyl group
of MI-4.

Therefore, alanine substitution was expected to change MI-4 binding by

eliminating the possibility of H-bond formation. However, WT-like affinity of MI-4 was
observed at D384A, implying that the proposed H-bond might not form.
The finding of MI-4, MI-15, MI-17 and MI-20 through VS experiments is
promising, although it might be argued that micromolar affinity is at best sub-optimal.
These compounds emerged from VS experiments utilizing a comparative protein model
with very low sequence similarity to its template (21%).

The percentage of “hit”

compounds is typically less than 1% of all compounds screened through VS or HTVS
(Bailey and Brown 2001; Schneider and Bohm 2002). Moreover, only low micromolar
activities are typically obtained when homology models and not X-ray structures of
targets are employed (Enyedy, Lee et al. 2001; Enyedy, Ling et al. 2001; Anand, Ziebuhr
et al. 2003; Rajnarayanan, Dakshanamurthy et al. 2004; Dong, Sheng et al. 2010).
Therefore, finding VS hits with nanomolar affinity was not expected.
Successful identification of MI-4, MI-15, MI-17 and MI-20 reflects a structurebased ligand discovery effort based on DAT inhibitor docking studies, supporting the
hypothesis that the external vestibule (S2) substrate/inhibitor binding site of DAT protein
can be used in in silico screening experiments to discover novel inhibitors or lead
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compounds. It was hoped that the VS experiment would yield an affordable commercial
compound that could serve as a lead compound for development of a medication that
modulated dopamine levels. The successful modification of the MI-17 indicated that this
is a proper strategy to discover lead compounds using the refined models for developing
novel anti-addiction medications as well as therapeutics to combat depression, anxiety,
Parkinson’s disease, narcolepsy, chronic pain, and other CNS-related maladies.
Moreover, reliable ligand-transporter protein docking poses could help identify binding
pocket residues to be tested via site-directed mutagenesis and subsequent pharmacology
characterization. The preliminary study of MI-4 partially confirmed the involvement of
R85 and D475 suggested by the docking results (Table 8). Thus, the results from
mutagenesis and pharmacological study will further fine-tune the DAT model.
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IV. SUMMARY
Our results may be of significance to ongoing efforts in the development of antiaddiction medications.

In addressing whether the 3D DAT model could be useful for

elucidating the ligand binding sites and aiding the rational design of novel therapeutics,
the site-directed mutant pharmacology has confirmed some of the prediction from the
DAT model, which is promising that the comparative DAT model is valid to some extent
and could be further used for ligand docking and virtual screening. Although some
postulated mutants displayed wildtype-like profiles, it is still valuable information to
refine the DAT model. In addition, one methylphenidate analog bearing modest DAT
affinity (363 ± 28 nM) was identified as potential non-tropane based photoaffinity probe
via pharmacological assays. This compound was further radiolabeled and successfully
incorporated into the DAT protein, suggesting the use to identify protein-ligand direct
contact at the amino acid level. The photoaffinity labeling study could also help to
validate and refine the DAT model. With respect to the ability of the DAT model to
discover novel DAT ligands, virtual screening experiments were done using the refined
DAT model. The top scored “hit” compounds were tested on bench, and 4 of them (MI-4,
MI-15, MI-17 and MI-20) were identified as potential DAT ligands with low µM affinity.
MI-4 also displayed affinities to SERT and NET. MI-17 displayed 4.5-fold higher
affinity at hSERT than at hDAT. A modification on MI-17 dramatically increased SERT
affinity without changing DAT affinity, indicating the successfully improved SERT/DAT
selectivity.
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The present study suggests the successful use of combined approaches including
molecular modeling, mutant pharmacology and photoaffinity labeling to identify
potential therapeutic compounds. The identification of MI-4, MI-15, MI-17 and MI-20
confirms the ability of the 3D model to screen and discover lead compounds for novel
therapeutics to combat addiction and other neurological and psychiatric conditions such
as Parkinson’s disease, depression, schizophrenia and ADHD.
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Figure 22.
Clomipramine inhibition of [3H]-WIN35,428 binding at N2A cells
transiently expressing WT or D384A DAT.
The inhibition of [3H]-WIN35,428 binding by clomipramine at N2A cells
transiently transfected with WT (●) or D384A (▲) DAT (n = 3 experiments).
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Figure 23.

Affinity and DUIP of modafinil at hDAT/N2A neuroblastoma cells.

Ki and IC50 values were derived from experiments incubating hDAT/N2A
neuroblastoma cells with modafinil in the presence of [3H]-WIN35,428 (upper panel) and
[3H]-dopamine (lower panel) at room temperature in KRH/AA buffer. Values represent
the mean ± SEM from at least three independent experiments, each conducted in
duplicate determinations.
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Figure 24.

Modafinil decreases the DUIP of cocaine.

The inhibition of [3H]-dopamine uptake by cocaine in the absence (●) or presence
(■) of 10 µM modafinil at hDAT/N2A neuroblastoma cells (n = 3 experiments).
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Table 9. Affinity of Modafinil at N2A neuroblastoma cells transiently expressing
DAT constructs.
Ki values were derived from experiments incubating transient transfected cells
with modafinil in the presence of [3H]-WIN35,428 at room temperature in KRH/AA
buffer. Values represent the mean ± SEM from three independent experiments, each
conducted in duplicate determinations (Only one experiment was done with T472A
DAT).
DAT Construct

DAT binding affinity
(Ki/µM)

WT

1.2 ± 0.3

R85D

5.8 ± 0.9*

R85D/D475R

4.8 ± 1.7

D384A

2.3 ± 0.3

T472A

2.0

* P < 0.05 vs. WT DAT
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Figure 25.
Inhibition of [3H]-WIN35,428 specific binding by cocaine, modafinil
and MI-4 at N2A cells expressing WT or mutant DAT proteins.
DAT binding affinities were assessed via [3H]-WIN35,428 displacement when
cocaine, modafinil and MI-4 (0.5 µM, 2 µM and 10 µM) were pre-incubated for cells
transiently transfected with plasmid encoding WT and mutated DATs. The data
represent an average of at least 3 separate experiments.
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APPENDIX 3

Figure 26. Initial DAT binding affinity and dopamine uptake inhibition screening
for VS “non-hit” compound at N2A neuroblastoma cells stably expressing WT
hDAT.
DAT binding affinities were assessed via [3H]-WIN35,428 displacement when
BS-1 to BS-9 (10 µM) were co-incubated (upper panel). [3H]-dopamine uptake
inhibition was assessed by incubation with BS-1 to BS-9 (10 µM) (lower panel). The data
represent an average of at least 3 separate experiments.
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Figure 27.
Affinity of WIN 35,428 at N2A neuroblastoma cells transiently
expressing HA tagged DAT.
Ki value was derived from experiments incubating transient transfected (HAtagged DAT) cells with nonradioactive WIN in the presence of [3H]-WIN35,428 at room
temperature in KRH/AA buffer. Value represents the mean ± SEM from three
independent experiments, each conducted in duplicate determinations.
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Figure 28.
T472 DAT.

Affinity of MI-4 at N2A neuroblastoma cells transiently expressing

Ki value was derived from experiments incubating transient transfected cells with
MI-4 in the presence of [3H]-WIN35,428 at room temperature in KRH/AA buffer. Value
represents the mean ± SEM from three independent experiments, each conducted in
duplicate determinations.
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APPENDIX 6
Melatonin is a neurohormone mainly secreted by the pineal gland that follows a
circadian rhythm with its highest concentrations at night. The cloning of genes encoding
melatonin receptors has revealed three melatonin receptor subtypes (MT1, MT2 and MT3).
The MT1 melatonin receptor belongs to the G-protein coupled receptor (GPCR)
superfamily. It is involved in modulating several physiological processes that triggered
by melatonin, such as circadian rhythm and constricting cardiac blood vessels. The
ability of melatonin to bind to, activate, and modulate MT1 receptors depends on the
interaction of melatonin with specific amino acids and/or domains.

Several highly

conserved structural “motifs” which are postulated to govern receptor function have been
uncovered by comparing GPCR amino acid sequences; MT1 receptor is unusual in its
divergence at these motifs. In order to test the hypothesis that one of these motifs, the
GPCR “aromatic cluster” motif in TM6 and its “toggle switch” position 6.52 are involved
in MT1 receptor ligand binding and activation, selective substitutions were made to the
amino acid comprising this motif and their effects on ligand binding were observed.
Aromatic cluster sequences
Most GPCRs:

“F6.44XXXW6.48XXXF6.52”

Melatonin receptor: “F6.44XXXW6.48XXXN6.52”
Transiently-transfected COS 7 cells and stable CHO cell lines expressing wild
type and mutant MT1 receptors were assayed for ligand binding. Asparagine (N) side
chain at position 6.52 is proposed to control the contribution of the aromatic cluster to
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receptor activation. Alanine (A) substitution of this amino functional group is predicted
to disrupt hydrogen-bonding potential while preserving helical structure. Phenylalanine
(F) substitution will add aromaticity and eliminate the hydrogen-bonding potential.
Histidine (H) substitution will keep the hydrogen-bonding potential while adding
aromaticity. All these alterations are proposed to disrupt the molecular interactions
within the receptor important for ligand recognition. The 1-point [125I]-iodomelatonin
binding assay (Fig 29) showed that only N6.52A displayed detectable binding, while
N6.52F and N6.52H failed to show any specific binding, suggesting that the increased
steric hindrance by adding aromatic ring to this position might be the reason for the loss
of ligand binding.

N6.52A MT1 receptor displayed WT-like binding affinity for

iodomelatonin (Fig 30, Table 10). Given the observation that the number of drugaccessible N6.52A MT1 molecules measured by maximal [125I]-iodomelatonin binding
(Bmax) was 3-fold lower than WT (Table 10), the loss of net binding (Fig 29, 30) can
largely be accounted for by the loss of MT1 expression. Competitive binding results
showed that antagonist luzindole Ki values higher for the mutant receptor (Fig 31, Table
11), implying that N6.52 amino acid residue might be more important for antagonist
binding than that of agonist. Binding assays involving structurally different ligands and
receptor mutagenesis will further evaluate the role of the aromatic motif in the function of
the MT1 receptor. Understanding these motif amino acids should be helpful in providing
a template for therapeutic drug design.
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Figure 29.
Determination of [125I]-iodomelatonin specific binding by COS 7 cells
expressing WT or N6.52 mutant MT1 receptor proteins.
The extent of specific [125I]-iodomelatonin binding as a percentage of WT MT1
was assessed for cells transiently transfected with plasmids encoding N6.52A, N6.52F,
N6.52H MT1, or the plasmid vector lacking MT1 sequence (pIRESneo). The data
represent an average of 3 separate experiments.
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Figure 30.
Specific [125I]-iodomelatonin binding at CHO cells stably expressing
WT or N6.52A MT1 receptor proteins.
Hot [125I]-iodomelatonin saturation binding was assessed for CHO cells stably
transfected with plasmids encoding WT or N6.52A MT1 receptor (n = 3 experiments).
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Table 10. Affinity of [125I]-iodomelatonin at CHO cells stably expressing MT1
constructs.
Kd and Bmax values were derived from experiments incubating stably transfected
CHO cells with [125I]-iodomelatonin. Values represent the mean ± SEM from three
independent experiments, each conducted in duplicate determinations.
MT1 Construct

Kd (pM)

Bmax (fmol/mg)

WT

92 ± 4

1074 ± 165

N6.52A

120 ± 9

312 ± 75*

* P < 0.05 vs. WT MT1
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Figure 31.
Specific [125I]-iodomelatonin binding at CHO cells stably expressing
WT or N6.52A MT1 receptor proteins.
Hot [125I]-iodomelatonin saturation binding was assessed for CHO cells stably transfected
with plasmids encoding WT or N6.52A MT1 receptor (n = 3 experiments).
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Table 11. Affinity of melatonin and luzindole at CHO cells stably expressing MT1
constructs.
Ki values were derived from experiments incubating stably transfected CHO cells
with nonradioactive melatonin or luzindole in the presence of [125I]-iodomelatonin.
Values represent the mean ± SEM from three independent experiments, each conducted
in duplicate determinations.
MT1 Construct

Melatonin

Luzindole

Ki (pM)

Ki (pM)

WT

24 ± 10

6.2 ± 3.8

N6.52A

29 ± 9

30 ± 22*

* P < 0.05 vs. WT MT1
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